

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Diagnosed prevalence of Ehlers-Danlos syndrome and Hypermobility Spectrum Disorder: a national electronic cohort study and case-control comparison

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-031365
Article Type:	Research
Date Submitted by the Author:	30-Apr-2019
Complete List of Authors:	Demmler, Joanne; Swansea University, Swansea University Medical School Atkinson, Mark; Swansea University, Swansea University Medical School Reinhold, Emma; Royal College of General Practitioners Choy, Ernest; Cardiff University, School of Medicine Lyons, Ronan; Swansea University, Swansea University Medical School Brophy, Sinead; Swansea University, Swansea University Medical School
Keywords:	Heritable Disorders of Connective Tissue, Ehlers-Danlos Syndromes, Joint Hypermobility Syndrome, Hypermobility Spectrum Disorder, Health Data Linkage, Prevalence

SCHOLARONE™
Manuscripts

Diagnosed prevalence of Ehlers-Danlos syndrome and Hypermobility Spectrum

Disorder: a national electronic cohort study and case-control comparison

Joanne C Demmler, Mark D Atkinson, Emma J Reinhold, Ernest Choy, Ronan A Lyons,
Sinead T Brophy

Joanne C Demmler, Lecturer, Health Data Research UK, Swansea University, Singleton
Park, Swansea SA2 8PP, UK. j.demmler@swansea.ac.uk.

Mark D Atkinson, Research Officer, Secure Anonymised Information Linkage (SAIL)
Databank, Swansea University, Singleton Park, Swansea SA2 8PP, UK.
m.atkinson@swansea.ac.uk.

Emma J Reinhold, RCGP Clinical Champion for the Ehlers-Danlos Syndromes, Clinical
Innovation and Research Centre, Royal College of General Practitioners, 30 Euston Square,
London, NW1 2FB. e.reinhold@doctors.org.uk.

Ernest Choy, Professor, Arthritis Research UK CREATE Centre, Section of Rheumatology,
Division of Infection and Immunity, Cardiff University, Cardiff CF14 4YS, UK.
ChoyEH@cardiff.ac.uk.

Ronan A Lyons, Professor, Health Data Research UK, Swansea University, Singleton Park,
Swansea SA2 8PP, UK. r.a.lyons@swansea.ac.uk.

Sinead T Brophy, Professor, Health Data Research UK, Swansea University, Singleton Park,
Swansea SA2 8PP, UK. s.brophy@swansea.ac.uk.

Correspondence to: JC Demmler j.demmler@swansea.ac.uk. Tel: 44 (0) 1792 295674

Abstract

Objectives: To describe the epidemiology of diagnosed Hypermobility Spectrum Disorder (HSD) and Ehlers-Danlos Syndromes (EDS) under the 2017 classification using linked electronic medical records. To examine whether these conditions remain rare and primarily affect the musculoskeletal system.

Design: Nationwide linked electronic cohort and nested case-control study

Setting: Routinely collected data from primary care and hospital admissions in Wales, UK.

Participants: People within the primary care or hospital data systems with a coded diagnosis of Ehlers-Danlos syndrome (EDS) or Joint Hypermobility Syndrome (JHS) between 01/07/1990 and 30/06/2017.

Main outcome measures: Combined prevalence of JHS and EDS in Wales. Additional diagnosis and prescription data in those diagnosed with EDS or JHS compared with matched controls.

Results: We found 6,021 individuals (male: 30%, female: 70%) with a diagnostic code of either EDS or JHS. This gives a diagnosed point prevalence of 194.2 per 100,000 in 2016/17 or roughly 10 cases in a practice of 5000 patients. There was a pronounced gender difference of 8.5 years (95% CI: 7.70 to 9.22) in the mean age at diagnosis. EDS or JHS was not only associated with high odds for other musculoskeletal diagnoses and drug prescriptions, but also with significantly higher odds of a diagnosis in other disease categories (e.g. mental health, nervous and digestive systems) and higher odds of a prescription in most disease categories (e.g. gastro-intestinal and cardiovascular drugs) within the 12 months before and after the first recorded diagnosis.

Conclusions: EDS and JHS (since March 2017 classified as EDS or HSD) have historically been considered rare diseases only affecting the musculoskeletal system and soft tissues. These data demonstrate that both of these assertions should be reconsidered.

1
2
3
4
5
6 **Key Words:** Heritable Disorders of Connective Tissue, Ehlers-Danlos Syndromes, Joint
7
8 Hypermobility Syndrome, Hypermobility Spectrum Disorder, Health Data Linkage,
9
10 Prevalence
11

12
13 **Word Count:** 3687
14
15

16 17 18 19 **Article Summary** 20

21 22 **Article focus** 23

- 24
25 ● To provide physicians with an overview of the epidemiology of Ehlers-Danlos
26
27 Syndromes; prevalence and co-morbidities.
28
- 29 ● EDS and other hereditary connective tissue disorders have been considered rare.
30
- 31 ● Early diagnosis is important, but there is often a long diagnostic delay.
32
- 33 ● Connective tissue disorders are recognised as affecting more than the
34
35 musculoskeletal system.
36
37

38 **Key messages** 39

- 40
41 ● JHS/EDS are now diagnosed at a rate of 1 in 500 meaning these conditions are not
42
43 rare.
44
- 45 ● These figures will significantly underestimate the true prevalence as they only reflect
46
47 diagnosed cases.
48
- 49 ● The conditions are associated with a high probability of additional diagnoses affecting
50
51 most body systems (e.g. mental health, nervous and digestive systems) in both
52
53 adults and children.
54
- 55 ● These findings have significant implications for policy makers and service planning.
56
57

58 **Strengths and Limitations** 59 60

- Large cohort and nested case-control studies based on whole population routinely collected health data from primary and secondary care
- We are unable to quantify how many people are suffering from hypermobile EDS (hEDS) or HSD but remain undiagnosed, nor can we make any statement on the reliability of the diagnoses
- Although we only compared codes at Read chapter level all diagnoses and prescriptions can be matched to conditions found in the EDS/JHS literature

Additional Resources

RCGP Clinical Toolkit on the Ehlers-Danlos Syndromes www.rcgp.org.uk/eds



RCGP Podcast "Introduction to Ehlers-Danlos Syndromes"

<https://audioboom.com/posts/6896541-introduction-to-ehlers-danlos-syndromes>

Introduction

The Ehlers-Danlos Syndromes (EDS) are a group of hereditary connective tissue disorders which mainly affect collagen. The nomenclature of these conditions has undergone a number of iterations which makes discussion of their prevalence complicated (see Textbox 1).

For many decades, studies have quoted a prevalence rate of 1 in 5000 for EDS, although the origin of this figure is unclear, seeming to appear first in a medical textbook^{1 2} as an unreferenced “reasonable estimate”. Thus, these syndromes have long been categorised as rare diseases, defined in the European Union as those affecting fewer than 50 in 100,000 people³. Kulas Søbørg et al.⁴ recently reported a prevalence of 20 per 100,000 for EDS in a nationwide Danish cohort based on secondary health care data up to 2012, but importantly, this data did not include patients who had received the considerably more common JHS diagnosis, now included in the latest revised classification. It is possible to extrapolate a combined population prevalence figure for JHS and EDS for Sweden⁵ of around 120 per 100,000 from a study focussing on comorbid mental health issues, but no investigators have thus far set out to investigate the combined diagnosed prevalence of JHS/EDS within a population.

Although common features of these conditions are arthralgia, soft tissue injury and joint instability⁶, over the last two decades it has become clear that their clinical features are not limited to musculoskeletal and cutaneous involvement, but are multisystemic⁷⁻⁹. In the special edition of the American Journal of Medical Genetics dedicated to EDS in March 2017, papers covered links to cardiovascular autonomic¹⁰ and gastrointestinal dysfunction¹¹ as well as psychiatric and neurodevelopmental disorders^{5 12}. Chronic disabling fatigue¹³ and pain syndromes¹⁴ were also recognised as common and multifactorial issues. Gynaecological^{15 16} and obstetric¹⁷ issues are also reported in this population. There is also an emerging link with the potentially life-threatening condition of Mast Cell Activation

1
2
3 Syndrome^{18 19}. There is some emerging evidence hinting that nutritional deficiencies^{20 21}
4 may play a key role, both seeming to be more prevalent in these patients and possibly
5 implicated in the development of some of the complications.
6
7
8

9
10 Early diagnosis is found to be crucial to patients²² to enable the provision of appropriate
11 treatment, as well as to prevent later onset complications⁷. Establishing the diagnosis of
12 EDS/HSD is often problematic for patients, which interferes with the early detection,
13 treatment and prevention of further escalations of recognised symptoms, disability and more
14 elaborate complications. A mean of 14 years elapses between the first clinical
15 manifestations and the actual diagnosis²³. For 25% of patients this delay lasts over 28 years
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
23. "A misdiagnosis was given to 56% of patients [resulting in] inappropriate treatment in 70%
of the patients... For 86% of the patients, the delay in diagnosis was considered responsible
for deleterious consequences." ^{23(p.137)}

It is possible that some of these difficulties arise from the widespread belief amongst
clinicians that EDS is rare. It is therefore of clinical importance to establish better estimates
of current prevalence. Conventional studies tend to be based in restricted clinical settings,
such as rheumatology clinics, and are therefore limited by the number of recruited patients
and biased by severity/type of patients referred. It has been shown that using linked health
data is an economic and effective alternative to performing *de novo* longitudinal studies,
including rare conditions^{24 25}. We used routinely held data from primary and secondary care
sources to examine the epidemiology of people with a diagnostic code for EDS/JHS in
Wales. We then conducted a nested case- control study to study the number of diagnoses
across all body/disease systems and prescription usage in order to test the widespread
belief that these conditions are primarily musculoskeletal in nature, rather than multi-system
disorders.

Methods

Study design: Nationwide electronic cohort study

Anonymised record linkage and hosting is carried out in the Secure Anonymised Information Linkage (SAIL) databank²⁶ on routinely collected data held in health and social care datasets. All data within the SAIL gateway are treated in accordance with the Data Protection Act 2018 and complies with GDPR.

We used data from a variety of datasets between 01/07/1990 and 30/06/2017 to create the anonymised e-cohort and case control studies. The Primary Care data covers about 80% of all coded information held by General Practitioners (GPs) in Wales. The Welsh Demographics Service (WDS) contains key statistics, such as gender, week of birth, date of death and practice migration status for everyone in Wales registered with a GP. The Patient Episode Database for Wales (PEDW) contains all inpatient hospital admissions to a Welsh hospital. WDS and PEDW data are available for the whole of Wales. The SAIL databank enables the anonymised matching of individuals across these different datasets using a person level anonymised linkage field (ALF)²⁶.

Cohort preparation

We identified Welsh residents with a Read Version 2²⁷ diagnostic code of EDS or JHS in primary care data or ICD-10 diagnostic codes²⁸ in secondary care data (hospital admissions) between 01/07/1990 (or the start of the dataset if later) and 30/06/2017. This date marks the end of maximum data coverage across all datasets. The EDS sub-classification in Read Version 2 contains some, but not all, of the subtypes which were in use prior to 1997 and as a result, the reliability of any subtype data must be highly questionable (see Table 1). ICD-10 codes do not distinguish between any subtypes of EDS (see Table 1). Only ALF's with good matching status were included in the study, i.e. direct match on either NHS number or on surname, first name, postcode, date of birth and gender; or fuzzy matching with a probability of $\geq 90\%$.

1
2
3 We created one dataset for diagnoses in the GP data and another for diagnoses in the
4 hospital data. Both datasets were linked to the week of birth, gender and date of death
5 information in WDS on their ALF and then combined to create a cohort of people with
6 EDS/JHS in either GP or hospital data, identifying any duplications and keeping the earliest
7 diagnosis date for any individual appearing in both datasets.
8
9
10
11
12

13 14 **Analysis**

15
16
17 Data linkage and data preparation within the SAIL databank were conducted using IBM DB2
18 10.5 SQL. Data were then imported into R (Version 3.4.1)²⁹, which was used for all
19 statistical analyses. The mean age at first diagnosis between male and female subjects was
20 compared and confidence intervals of the difference calculated.
21
22
23
24
25

26 The denominator of the diagnosed prevalence and incidence of EDS and JHS in secondary
27 care was calculated based on the total number of individuals with recorded gender,
28 registered and living in Wales between 01/07/1990 and 30/06/2017 for each full year of the
29 study respectively. The prevalence and incidence in primary care denominator was further
30 adjusted to include only people living in Wales and whose GP practice was contributing data
31 to SAIL. The prevalence and incidence in primary and secondary care was then added
32 together to create an overall estimate of the prevalence and incidence in Wales.
33
34
35
36
37
38
39
40

41 **Case-Control Comparison**

42
43
44 A nested case control method was used. Each case was matched to 4 controls with the
45 same gender and similar age profiles (within 45 days of the week of birth). We implemented
46 strict criteria for selection to the case-control cohort. Both cases and controls had to (a) have
47 uninterrupted GP registrations for 1 year before and 1 year after the date of the relevant
48 diagnosis (or died during follow-up); (b) be registered with a GP submitting data to SAIL
49 either at the matching date or afterwards; (c) have been registered with a GP that
50 consistently recorded data across their patient profile. The latter avoids diagnoses that were
51 retrospectively entered for a time period when the GP practice did not fully implement the
52
53
54
55
56
57
58
59
60

1
2
3 use of electronic records (less than 10% of the data they recorded during 2009). Although
4 this reduced the number of cases and controls we were able to analyse, it avoids data
5 quality bias, especially during the early years of this study, when GPs were converting to the
6 use of computer systems and databases. Controls with any type of diagnosed hereditary
7 connective tissue disorder were excluded. Preliminary analysis of the combined cohort
8 indicated that adjustment for deprivation was not necessary (i.e. equal distribution of people
9 across deprivation quintiles). We then calculated odds ratios between cases and controls
10 using Read chapters. All results that affected at least 5 cases or 20 controls were visualised
11 using forest plots.
12
13
14
15
16
17
18
19
20
21
22

23 **Ethical approval**

24
25 The study design uses anonymised data and therefore the need for ethical approval and
26 participant consent was waived by the approving Institutional Review Board, the UK National
27 Health Service Research Ethics Committee. The SAIL independent Information Governance
28 Review Panel (IGRP) approved the study.
29
30
31
32
33

34 **Patient and Public Involvement**

35
36 Two of the authors of this paper have been diagnosed with symptomatic joint hypermobility
37 disorders. This study used routinely collected data, we were not able to involve members of
38 the public but will be disseminating our findings widely, including directly to patients via
39 social media and through our links with patient organisations.
40
41
42
43
44
45

46 **Results**

47 **EDS/JHS in Primary Care data**

48
49 5,355 individuals with a diagnosis of either EDS or JHS with valid birth and gender
50 information were identified. Of these, 4,654 (87%) had a diagnosis of JHS and 701 (13%) of
51 EDS. The Read code for the EDS subtype was only used for 136 (19%) individuals with 114
52
53
54
55
56
57
58
59
60

1
2
3 (16%) identified as EDS-Hypermobility Type and 22 (3%) as other EDS subtypes. 3,759
4
5 (70%) of those diagnosed with EDS/JHS were female (see Figure 1).
6
7

8 **EDS/JHS in Hospital Data**

9

10
11 A total of 1,298 individuals were found in the hospital data of whom 970 (75%) were female:
12
13 745 (57%) had a diagnosis of JHS and 553 (43%) EDS (see Figure 1).
14

15 **Demographics of combined EDS/JHS cohort**

16

17
18 5,355 (89%) of the cases could be found in the primary care data with the remainder in the
19
20 hospital cohort. Combining the results from primary and secondary care led to a cohort of
21
22 6,021 distinct individuals. 5,064 (84%) were coded with JHS and 957 (16%) with EDS. 4,244
23
24 (70%) of patients were female. The age at first diagnosis peaked in the age group 5-9 years
25
26 for males and 15-19 years for females (see Figure 2). There was a significant difference of
27
28 8.5 years in the mean age of diagnosis between males and females (95% CI: 7.70 to 9.22):
29
30 9.6 years in EDS (95% CI: 6.85 to 12.31) and 8.3 years in JHS (95% CI: 7.58 to 9.11). 72%
31
32 of males were diagnosed during childhood (age < 18 years) in contrast to only 41% of
33
34 females.
35
36

37
38 2016/17 is the latest year for which we have complete data and could therefore derive
39
40 prevalence. During this year, 2,668,902 people were registered with a GP in Wales
41
42 submitting data to SAIL, of whom 4,598 had a diagnostic code of EDS/JHS which first
43
44 appeared in the primary care data (172 in 100,000). A further 711 people out of the
45
46 3,239,153 registered with any GP in Wales during 2016/17 had an EDS/JHS diagnosis
47
48 which first appears in secondary care data (22 in 100,000). There is an increasing rate of
49
50 coded diagnoses throughout the period. Assuming that the GP data is representative of the
51
52 whole of Wales this leads to a combined point prevalence of 194 in 100,000 at the end of the
53
54 study period. This corresponds to about 10 cases in a practice of 5000 patients (see Figure
55
56 3). The incidence of EDS/JHS over this time period is shown in Supplement Figure 1.
57
58
59

60 **Factors associated with JHS/EDS**

1
2
3 2,597 cases had good GP data coverage at the age of diagnosis and could be matched by
4 age and gender with controls (see Figure 1). 1,340 cases (male: 561; female: 779) were first
5 diagnosed before the age of 18 years and 1,254 cases (male: 229; female: 1,025) above this
6 age. The people in the nested case-control cohort were slightly older than the overall cohort
7 (data not shown here).
8
9

10
11
12
13
14 Looking at the time frame of 1 year either side of the first coded diagnosis of EDS/JHS
15 amongst young people (age < 18 years) there were significantly more additional diagnoses
16 in 16 out of 20 Read code disease categories compared with their controls (see Figure 4a).
17
18 The top three Read diagnosis chapters with increased odds for the EDS/JHS cohort were for
19 musculoskeletal conditions (OR 9.36, 95% CI: 7.98 to 11.00), congenital anomalies (OR
20 5.89; 95% CI: 3.98 to 8.80) and mental disorders (OR 4.16; 95% CI: 3.29 to 5.27).
21
22

23
24
25
26
27 People that were diagnosed as adults (age >= 18 years) had also significantly more
28 diagnoses in 16 out of 20 Read code categories than their controls. The top three Read
29 diagnosis chapters for adults with higher odds in the EDS/JHS cohort were musculoskeletal
30 disorders (OR 7.95; 95% CI: 6.95 to 9.12), congenital anomalies (OR 5.18; 95% CI: 2.78 to
31 9.78) and symptoms, signs and ill-defined conditions (OR 2.9; 95% CI: 2.5 to 3.37).
32
33

34
35
36
37
38 Circulatory system disease (OR 2.29; 95% CI: 1.83 to 2.86) and mental disorders remained
39 significant (OR 1.87; 95% CI: 1.57 to 2.22), but not to the same extent as they were for
40 young people.
41
42
43
44

45
46
47
48
49 Young people showed significantly higher odds for prescriptions in 14 out of 17 Read code
50 categories than their controls (see Figure 5a). The top three prescriptions Read chapters
51 with increased odds for the EDS/JHS cohort were for (i) musculoskeletal drugs (OR 3.65;
52 95% CI: 3.18 to 4.18), (ii) gastro-intestinal drugs (OR 3.02; 95% CI: 2.54 to 3.58) and (iii)
53 haematology/dietetic drugs (OR 2.54; 95% CI: 2.06 to 3.11).
54
55

56
57
58
59
60 Adults had significantly higher odds of prescriptions for 15 out of 17 Read code categories
(see Figure 5b). The top three prescriptions with higher odds for EDS/JHS people were for

1
2
3 (i) musculoskeletal drugs (OR 5.17; 95% CI: 4.53 to 5.9), (ii) central nervous system drugs
4 (OR 3.9; 95% CI: 3.41 to 4.46) and (iii) chemotherapy/immunosuppressant drugs (OR 3.03;
5 95% CI: 1.89 to 4.8). Gastro-intestinal drugs (OR 2.85; 95% CI: 2.5 to 3.24) and
6
7 haematology/dietetic drugs (OR 2.21; 95% CI: 1.9 to 2.57) remain significant, but at slightly
8
9 lower levels than in the young EDS/JHS population.
10
11
12

13 14 15 **Discussion**

16
17
18 This work examined the epidemiology of EDS and JHS and found a combined diagnosed
19 prevalence of 194.2 per 100,000 (0.19%), or 1 in 500 people in Wales; hEDS or HSD within
20 the 2017 classification. We found a steadily increasing rate of diagnosis over the past 27
21 years (see Supplement Figure 1), as well as higher rates of diagnoses for other conditions
22 and prescriptions within 12 months (pre and post) of the recorded first diagnosis in most
23 categories. This suggests that hEDS/HSD, when considered together, do not meet the
24 definition of rare conditions²³, and have widespread effects across multiple body systems.
25 It is well-known that EDS is poorly recognised in children^{30 31}. Furthermore, children with
26 hEDS often present with symptoms that can lead to a misdiagnosis of mental illness or
27 consideration of child abuse^{12 32}. Suspicion of abuse has been shown to be extremely
28 damaging to the mental health of the parent(s) and can lead to an avoidance of accessing
29 health care or other public services, such as schools³³. The prolonged and sometimes
30 traumatic diagnosis and/or misdiagnosis process in EDS can lead to further disengagement
31 with services³⁴. The lack of a timely diagnosis has great implications for disease
32 management and progression and impedes the appropriate consideration of surgical
33 interventions^{7 35-38} as well as pregnancy and birth planning¹⁷.
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50

51 52 **Strengths and Limitations**

53
54
55 The strength of this study is that we were able to combine diagnostic codes from several
56 primary and secondary health care providers to create a large cohort of individuals with
57 EDS/JHS. We have 27 years of data with at least 11 years of very good data coverage in the
58
59
60

1
2
3 key datasets, which further improves with each data update of the SAIL databank, however
4 data coverage for the first couple of years is less comprehensive.
5
6

7
8 The majority of subjects were identified via their primary care data, which is a strength and a
9 weakness. As 89% of cases were identified through primary care data studies not using
10 primary care data may underestimate the prevalence of hEDS/HSD. We are unable to
11 quantify how many people are suffering from hEDS or HSD but remain undiagnosed.
12
13

14
15 However, we cannot comment on the reliability of the diagnoses in the primary care dataset.
16

17
18 It is also likely that the majority of cases were not actually diagnosed in primary care, but
19 their entries were created through secondary care contacts, such as outpatient appointments
20 or musculoskeletal assessment clinics, but coded data are lacking from these sources.
21
22
23

24
25 Although a snapshot of Read chapters codes that are more prevalent in our JHS/EDS cohort
26 does not allow us to look at specific diagnoses and prescriptions, they can all be matched to
27 conditions associated with EDS/JHS in the literature, for instance pain, fatigue,
28 cardiovascular, gastrointestinal and gynaecological disorders, dysautonomia, mast cell
29 activation as well as urinary tract infections ⁷.
30
31
32
33
34
35

36
37 We conclude that EDS/HSD are not rare conditions and are associated with significantly
38 increased odds of additional diagnoses and use of medications across many body systems.
39

40
41 There is a large gender difference in the age of diagnosis, with many women not diagnosed
42 until adulthood. Early diagnosis, however, is crucial to patients, the administration of
43 preventive therapies, the investigation of comorbid conditions and the overall management
44 process. Further research is needed to understand patient pathways, comorbidities and
45 progression of associated symptoms and diseases. Health services should be aware of
46 these findings for the provision of training, diagnostic and treatment services for the many
47 tens of thousands of patients living with these life-changing conditions throughout the United
48 Kingdom and beyond.
49
50
51
52
53
54
55
56
57

58 **Author contributions**

59
60

1
2
3 JD conceived the project. SB and MA contributed to the study design and analysis plan. RAL
4 validated clinical codes in primary care. EC validated clinical codes in secondary care. JD
5 undertook the analysis. JD and ER carried out the literature reviews and drafted the
6 manuscript. All authors reviewed the manuscript and approved the final version for
7 submission.
8
9
10
11
12
13
14
15

16 **Funding**

17
18 This work was supported by The Farr Institute. The Farr Institute was supported by a 10-
19 funder consortium: Arthritis Research UK, the British Heart Foundation, Cancer Research
20 UK, the Economic and Social Research Council, the Engineering and Physical Sciences
21 Research Council, the Medical Research Council, the National Institute of Health Research,
22 the National Institute for Social Care and Health Research (Welsh Assembly Government),
23 the Chief Scientist Office (Scottish Government Health Directorates), the Wellcome Trust,
24 (MRC Grant No: MR/K006525/1).
25
26
27
28
29
30
31
32

33 This work was also supported by Health Data Research UK which receives its funding from
34 HDR UK Ltd (NIWA1) funded by the UK Medical Research Council, Engineering and
35 Physical Sciences Research Council, Economic and Social Research Council, Department
36 of Health and Social Care (England), Chief Scientist Office of the Scottish Government
37 Health and Social Care Directorates, Health and Social Care Research and Development
38 Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart
39 Foundation (BHF) and the Wellcome Trust.
40
41
42
43
44
45
46
47
48

49 The above funders played no role in the study design, in the collection, analysis, or
50 interpretation of data; in the writing of the report; or in the decision to submit the article for
51 publication. The researchers are independent from the funders and all authors, external and
52 internal, had full access to all of the data in the study and take responsibility for the integrity
53 of the data and the accuracy of the data analysis.
54
55
56
57
58
59
60

1
2
3 Competing interests: All authors have completed the ICMJE uniform disclosure form at
4 www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the
5 submitted work; no financial relationships with any organisations that might have an interest
6 in the submitted work in the previous three years; no other relationships or activities that
7 could appear to have influenced the submitted work.
8
9
10
11
12

13
14
15 Exclusive licence: The Corresponding Author has the right to grant on behalf of all authors
16 and does grant on behalf of all authors, a worldwide licence
17 (<http://www.bmj.com/sites/default/files/BMJ%20Author%20Licence%20March%202013.doc>)
18 to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether
19 known now or created in the future), to i) publish, reproduce, distribute, display and store the
20 Contribution, ii) translate the Contribution into other languages, create adaptations, reprints,
21 include within collections and create summaries, extracts and/or, abstracts of the
22 Contribution and convert or allow conversion into any format including without limitation
23 audio, iii) create any other derivative work(s) based in whole or part on the on the
24 Contribution, iv) to exploit all subsidiary rights to exploit all subsidiary rights that currently
25 exist or as may exist in the future in the Contribution, v) the inclusion of electronic links from
26 the Contribution to third party material wherever it may be located; and, vi) licence any third
27 party to do any or all of the above. All research articles will be made available on an open
28 access basis (with authors being asked to pay an open access fee—see
29 [http://www.bmj.com/about-bmj/resources-authors/forms-policies-and-checklists/copyright-](http://www.bmj.com/about-bmj/resources-authors/forms-policies-and-checklists/copyright-open-access-and-permission-reuse)
30 [open-access-and-permission-reuse](http://www.bmj.com/about-bmj/resources-authors/forms-policies-and-checklists/copyright-open-access-and-permission-reuse)). The terms of such open access shall be governed by a
31 Creative Commons licence—details as to which Creative Commons licence will apply to the
32 research article are set out in our worldwide licence referred to above.
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53

54
55 Transparency declaration: The lead author affirms that this manuscript is an honest,
56 accurate, and transparent account of the study being reported; that no important aspects of
57
58
59
60

1
2
3 the study have been omitted; and that any discrepancies from the study as planned (and, if
4 relevant, registered) have been explained.
5
6
7
8

9 Dissemination statement: We are planning to disseminate our results to patient groups using
10 social media.
11
12
13

14
15
16 Data sharing statement: The data used in this study are available in the SAIL databank at
17 Swansea University, Swansea, UK. All proposals to use SAIL data are subject to review by
18 an independent Information Governance Review Panel (IGRP). Before any data can be
19 accessed, approval must be given by the IGRP.
20
21
22
23

24 The IGRP gives careful consideration to each project to ensure proper and appropriate use
25 of SAIL data. When access has been granted, it is gained through a privacy-protecting safe
26 haven and remote access system referred to as the SAIL Gateway. SAIL has established an
27 application process to be followed by anyone who would like to access data via SAIL
28 <https://www.saildatabank.com/application-process>
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Cecil RLF, Goldman L, Bennett JC. Cecil Textbook of Medicine: W.B. Saunders 2000.
2. Mulvey MR, Macfarlane GJ, Beasley M, et al. Modest Association of Joint Hypermobility With Disabling and Limiting Musculoskeletal Pain: Results From a Large-Scale General Population-Based Survey. *Arthritis Care & Research* 2013;65(8):1325-33. doi: 10.1002/acr.21979
3. Commission of the European Communities Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the regions on Rare Diseases: Europe's challenges. Brussels: Commission of the European Communities, 2008.
4. Søborg M-LK, Leganger J, Mortensen LQ, et al. Establishment and baseline characteristics of a nationwide Danish cohort of patients with Ehlers–Danlos syndrome. *Rheumatology (Oxford)* 2017;56(5):763-67. doi: 10.1093/rheumatology/kew478
5. Cederlöf M, Larsson H, Lichtenstein P, et al. Nationwide population-based cohort study of psychiatric disorders in individuals with Ehlers-Danlos syndrome or hypermobility syndrome and their siblings. *Bmc Psychiatry* 2016;16 doi: 10.1186/s12888-016-0922-6
6. Hakim AJ, Grahame R. A simple questionnaire to detect hypermobility: An adjunct to the assessment of patients with diffuse musculoskeletal pain. *International Journal of Clinical Practice* 2003;57(3):163-66.
7. Tinkle B, Castori M, Berglund B, et al. Hypermobility Ehlers-Danlos Syndrome (a.k.a. Ehlers-Danlos Syndrome Type III and Ehlers-Danlos Syndrome Hypermobility Type): Clinical Description and Natural History. *American Journal of Medical Genetics Part C-Seminars in Medical Genetics* 2017;175(1):48-69. doi: 10.1002/ajmg.c.31538
8. Gazit Y, Jacob G, Grahame R. Ehlers-Danlos Syndrome-Hypermobility Type: A Much Neglected Multisystemic Disorder. *Rambam Maimonides Medical Journal* 2016;7(4) doi: 10.5041/rmmj.10261
9. De Paepe A, Malfait F. The Ehlers-Danlos syndrome, a disorder with many faces. *Clinical Genetics* 2012;82(1):1-11. doi: 10.1111/j.1399-0004.2012.01858.x
10. Hakim A, O'Callaghan C, De Wandele I, et al. Cardiovascular Autonomic Dysfunction in Ehlers-Danlos Syndrome-Hypermobility Type. *American Journal of Medical Genetics Part C-Seminars in Medical Genetics* 2017;175(1):168-74. doi: 10.1002/ajmg.c.31543
11. Fikree A, Chelimsky G, Collins H, et al. Gastrointestinal Involvement in the Ehlers-Danlos Syndromes. *American Journal of Medical Genetics Part C-Seminars in Medical Genetics* 2017;175(1):181-87. doi: 10.1002/ajmg.c.31546
12. Bulbena A, Baeza-Velasco C, Bulbena-Cabre A, et al. Psychiatric and Psychological Aspects in the Ehlers-Danlos Syndromes. *American Journal of Medical Genetics Part C-Seminars in Medical Genetics* 2017;175(1):237-45. doi: 10.1002/ajmg.c.31544
13. Hakim A, De Wandele I, O'Callaghan C, et al. Chronic Fatigue in Ehlers-Danlos Syndrome-Hypermobility Type. *American Journal of Medical Genetics Part C-Seminars in Medical Genetics* 2017;175(1):175-80. doi: 10.1002/ajmg.c.31542
14. Chopra P, Tinkle B, Hamonet C, et al. Pain Management in the Ehlers-Danlos Syndromes. *American Journal of Medical Genetics Part C-Seminars in Medical Genetics* 2017;175(1):212-19. doi: 10.1002/ajmg.c.31554
15. Veit-Rubin N, Cartwright R, Singh AU, et al. Association between joint hypermobility and pelvic organ prolapse in women: a systematic review and meta-analysis. *International Urogynecology Journal* 2016;27(10):1469-78. doi: 10.1007/s00192-015-2896-1
16. Hugon-Rodin J, Lebegue G, Becourt S, et al. Gynecologic symptoms and the influence on reproductive life in 386 women with hypermobility type ehlers-danlos syndrome: a

- cohort study. *Orphanet Journal of Rare Diseases* 2016;11 doi: 10.1186/s13023-016-0511-2
17. Pezaro S, Pearce G, Reinhold E. Hypermobility Ehlers-Danlos Syndrome during pregnancy, birth and beyond. *British Journal of Midwifery* 2018;26(4):217-23. doi: 10.12968/bjom.2018.26.4.217
 18. Seneviratne SL, Maitland A, Afrin L. Mast Cell Disorders in Ehlers-Danlos Syndrome. *American Journal of Medical Genetics Part C-Seminars in Medical Genetics* 2017;175(1):226-36. doi: 10.1002/ajmg.c.31555
 19. Cheung I, Vadas P. A New Disease Cluster: Mast Cell Activation Syndrome, Postural Orthostatic Tachycardia Syndrome, and Ehlers-Danlos Syndrome. *Journal of Allergy and Clinical Immunology* 2015;135(2):AB65-AB65.
 20. Mantle D, Wilkins RM, Preedy V. A novel therapeutic strategy for Ehlers-Danlos syndrome based on nutritional supplements. *Medical Hypotheses* 2005;64(2):279-83. doi: 10.1016/j.mehy.2004.07.023
 21. Castori M, Morlino S, Pascolini G, et al. Gastrointestinal and Nutritional Issues in Joint Hypermobility Syndrome/Ehlers-Danlos Syndrome, Hypermobility Type. *American Journal of Medical Genetics Part C-Seminars in Medical Genetics* 2015;169(1):54-75. doi: 10.1002/ajmg.c.31431
 22. Terry RH, Palmer ST, Rimes KA, et al. Living with joint hypermobility syndrome: patient experiences of diagnosis, referral and self-care. *Family Practice* 2015;32(3):354-58. doi: 10.1093/fampra/cmz026
 23. EURORDIS AKFF. The Voice of 12,000 Patients. Experiences and Expectations of Rare Disease Patients on Diagnosis and Care in Europe: Eurordis 2009.
 24. Holman CDJ, Bass AJ, Rosman DL, et al. A decade of data linkage in Western Australia: strategic design, applications and benefits of the WA data linkage system. *Australian Health Review* 2008;32(4):766-77.
 25. Cooksey R, Husain MJ, Brophy S, et al. The Cost of Ankylosing Spondylitis in the UK Using Linked Routine and Patient-Reported Survey Data. *Plos One* 2015;10(7) doi: 10.1371/journal.pone.0126105
 26. Lyons RA, Jones KH, John G, et al. The SAIL databank: linking multiple health and social care datasets. *Bmc Medical Informatics and Decision Making* 2009;9 doi: 10.1186/1472-6947-9-3
 27. Chisholm J. The READ Clinical Classification. *Brit Med J* 1990;300(6732):1092-92.
 28. World Health Organization. ICD-10: International statistical classification of diseases and related health problems: World Health Organization 2016.
 29. R: A Language and Environment for Statistical Computing [program]. Vienna, Austria: R Foundation for Statistical Computing, 2017.
 30. Adib N, Davies K, Grahame R, et al. Joint hypermobility syndrome in childhood. A not so benign multisystem disorder? *Rheumatology* 2005;44(6):744-50. doi: 10.1093/rheumatology/keh557
 31. Grahame R, Hakim AJ. Joint Hypermobility Syndrome is highly prevalent in general rheumatology clinics, its occurrence and clinical presentation being gender, age and race-related. *Annals of the Rheumatic Diseases* 2006;65:263-63.
 32. Castori M. Ehlers-Danlos Syndrome(s) Mimicking Child Abuse: Is There an Impact on Clinical Practice? (vol 169, pg 289, 2015). *American Journal of Medical Genetics Part A* 2016;170(7):1947-47. doi: 10.1002/ajmg.a.37733
 33. Association for Improvements in Maternity Services (AIMS). The Child Protection System in England: Written evidence submitted by the Association for Improvements in the Maternity Services (AIMS) 2011 [Available from: <http://www.publications.parliament.uk/pa/cm201012/cmselect/cmeduc/writev/1514/cp29.htm> accessed 14/02/2019.
 34. Berglund B, Anne-Cathrine M, Randers I. Dignity not fully upheld when seeking health care: Experiences expressed by individuals suffering from Ehlers-Danlos syndrome. *Disability and Rehabilitation* 2010;32(1):1-7. doi: 10.3109/09638280903178407

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
35. Scheper MC, Nicholson LL, Adams RD, et al. The natural history of children with joint hypermobility syndrome and Ehlers-Danlos hypermobility type: a longitudinal cohort study. *Rheumatology* 2017;56(12):2073-83. doi: 10.1093/rheumatology/kex148
 36. Engelbert RHH, Juul-Kristensen B, Pacey V, et al. The Evidence-Based Rationale for Physical Therapy Treatment of Children, Adolescents, and Adults Diagnosed With Joint Hypermobility Syndrome/Hypermobility Ehlers Danlos Syndrome. *American Journal of Medical Genetics Part C-Seminars in Medical Genetics* 2017;175(1):158-67. doi: 10.1002/ajmg.c.31545
 37. Ericson WB, Wolman R. Orthopaedic Management of the Ehlers-Danlos Syndromes. *American Journal of Medical Genetics Part C-Seminars in Medical Genetics* 2017;175(1):188-94. doi: 10.1002/ajmg.c.31551
 38. Soborg MLK, Leganger J, Rosenberg J, et al. Increased Need for Gastrointestinal Surgery and Increased Risk of Surgery-Related Complications in Patients with Ehlers-Danlos Syndrome: A Systematic Review. *Digestive Surgery* 2017;34(2):161-70. doi: 10.1159/000449106
 39. Sobey G. Ehlers-Danlos syndrome: how to diagnose and when to perform genetic tests. *Archives of Disease in Childhood* 2015;100(1):57-61. doi: 10.1136/archdischild-2013-304822
 40. Grahame R, Bird HA, Child A, et al. The revised (Brighton 1998) criteria for the diagnosis of benign joint hypermobility syndrome (BJHS). *Journal of Rheumatology* 2000;27(7):1777-79.
 41. Beighton P, De Paepe A, Steinmann B, et al. Ehlers-Danlos syndromes: Revised nosology, Villefranche, 1997. *American Journal of Medical Genetics* 1998;77(1):31-37. doi: 10.1002/(sici)1096-8628(19980428)77:1<31::aid-ajmg8>3.0.co;2-o
 42. Grahame R. Joint hypermobility and genetic collagen disorders: are they related? *Archives of Disease in Childhood* 1999;80(2):188-91.
 43. Malfait F, Francomano C, Byers P, et al. The 2017 International Classification of the Ehlers-Danlos Syndromes. *American Journal of Medical Genetics Part C-Seminars in Medical Genetics* 2017;175(1):8-26. doi: 10.1002/ajmg.c.31552
 44. Castori M, Dordoni C, Morlino S, et al. Spectrum of Mucocutaneous Manifestations in 277 Patients with Joint Hypermobility Syndrome/Ehlers-Danlos Syndrome, Hypermobility Type. *American Journal of Medical Genetics Part C-Seminars in Medical Genetics* 2015;169(1):43-53. doi: 10.1002/ajmg.c.31425

Table 1: Clinical coding for Ehlers-Danlos Syndromes and Joint Hypermobility Syndrome.

Read code descriptions (based on pre-1997 nomenclature)	EDS type according to the Villefranche Criteria	EDS Type according to the March 2017 Criteria	Read code version 2	ICD10 code
Ehlers-Danlos syndrome			PGy2.	Q79.6
Ehlers-Danlos syndrome type I	Classical type	Classical EDS	PGy20	
Ehlers-Danlos syndrome type II			PGy21	
Ehlers-Danlos syndrome type III	Hypermobility type	Hypermobile EDS or Hypermobility Spectrum Disorder	PGy22	
Ehlers-Danlos syndrome type IV	Vascular type	Vascular EDS	PGy23	
Ehlers-Danlos syndrome type V	X-linked type	No longer classified as EDS	PGy24	
Ehlers-Danlos syndrome type VI	Kyphoscoliotic type	Kyphoscoliotic EDS	PGy25	
Ehlers-Danlos syndrome type VII	Arthrochalasia type Dermatosparaxis type	Arthrochalasia EDS Dermatosparaxis EDS	PGy26	
Ehlers-Danlos syndrome type VIII	Periodontitis type	Periodontal EDS	PGy27	
Hypermobility Syndrome (JHS according to the Brighton Criteria)	(Hypermobility type)	Hypermobile EDS or Hypermobility Spectrum Disorder	N235.	728.5

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1: Flow diagram of EDS/JHS cohort and case-control cohort creation




Figure 2: Age at first coded diagnosis of EDS/JHS by age group and gender




Figure 3: Prevalence of coded diagnosis of JHS/EDS in Primary Care, hospital inpatient and combined over time.




Figure 4: Odds ratios of Read chapter diagnoses for (a) young people (<18 years of age) and (b) adults (>= 18 years of age) within 12 months before and after EDS/JHS diagnosis. Presented are all results that affect at least 5 cases or 20 controls (perinatal conditions, chapter Q, are not shown as neither young people nor adults had the required minimum number of cases/controls).





Figure 5: Odds ratios of Read chapter prescriptions for young people (<18 years of age) and adults (>= 18 years of age) within 12 months before and after EDS/JHS diagnosis.

Presented are all results that affect at least 5 cases or 20 controls (incontinence and stoma appliances, chapters q and s, are not shown as neither young people nor adults had the required minimum number of cases/results).




Supplement Figure 1: Incidence of diagnosis of JHS/EDS in GP, hospital inpatient and combined data over time.

Textbox 1


Ehlers Danlos Syndrome Nomenclature

- Joint hypermobility *per se* is reasonably common and thought to be present in around 10% of the general UK population ³⁹.
- The Brighton criteria were used to diagnose Joint Hypermobility Syndrome from 1998 ⁴⁰,
- The Villefranche criteria were applied to confirm EDS-Hypermobility Type from 1997 ⁴¹.
- Prior to the Villefranche criteria, the diagnosis EDS III was used to denote the hypermobile subtype of EDS.
- It was recognised over a number of years that JHS and EDS-HT were not distinct from one another ⁴².
- In March 2017 the International Consortium on the Ehlers Danlos Syndromes published a revised classification ⁴³ naming two syndromes:
 - Hypermobile EDS (hEDS) which has narrowly defined criteria
 - Hypermobility Spectrum Disorder (HSD) for those with some but not all of the features of hEDS
- Patients who have a diagnosis of EDS-HT or JHS will fall into one of these two new categories.
- Castori et al showed that patients may move from the HSD category into hEDS over time: they also emphasised that the approach to management and the prognosis in terms of disability are the same ⁴⁴. One may therefore conclude that health needs across these groups are similar.



Flow diagram of EDS/JHS cohort and case-control cohort creation


209x297mm (300 x 300 DPI)



Age at first coded diagnosis of EDS/JHS by age group and gender


177x152mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Prevalence of coded diagnosis of JHS/EDS in Primary Care, hospital inpatient and combined over time

177x152mm (300 x 300 DPI)



Odds ratios of Read chapter diagnoses for (a) young people (<18 years of age) and (b) adults (>= 18 years of age) within 12 months before and after EDS/JHS diagnosis. Presented are all results that affect at least 5 cases or 20 controls (perinatal conditions, chapter Q, are not shown as neither young people nor adults had the required minimum number of cases/controls)


177x127mm (300 x 300 DPI)



Odds ratios of Read chapter prescriptions for young people (<18 years of age) and adults (>= 18 years of age) within 12 months before and after EDS/JHS diagnosis. Presented are all results that affect at least 5 cases or 20 controls (incontinence and stoma appliances, chapters q and s, are not shown as neither young people nor adults had the required minimum number of cases/results)

177x127mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



177x152mm (300 x 300 DPI)

The RECORD statement – checklist of items, extended from the STROBE statement, that should be reported in observational studies using routinely collected health data.

	Item No.	STROBE items	Location in manuscript where items are reported	RECORD items	Location in manuscript where items are reported
Title and abstract					
	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found	Title and abstract	RECORD 1.1: The type of data used should be specified in the title or abstract. When possible, the name of the databases used should be included. RECORD 1.2: If applicable the geographic region and timeframe within which the study took place should be reported in the title or abstract. RECORD 1.3: If linkage between databases was conducted for the study, this should be clearly stated in the title or abstract.	Abstract p. 2 Abstract p. 2 Abstract p. 2
Introduction					
Background rationale	2	Explain the scientific background and rationale for the investigation being reported			Introduction p. 5-6
Objectives	3	State specific objectives, including any prespecified hypotheses			Introduction p. 6
Methods					
Study Design	4	Present key elements of study design early in the paper			Methods p. 7-9
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection			Methods p. 7-9
Participants	6	(a) <i>Cohort study</i> - Give the eligibility criteria, and the		RECORD 6.1: The methods of study population selection (such as codes or	Methods p. 7-9 Table 1

36/bmjopen-2024-019031365
Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

		<p>sources and methods of selection of participants. Describe methods of follow-up</p> <p><i>Case-control study</i> - Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls</p> <p><i>Cross-sectional study</i> - Give the eligibility criteria, and the sources and methods of selection of participants</p> <p>(b) <i>Cohort study</i> - For matched studies, give matching criteria and number of exposed and unexposed</p> <p><i>Case-control study</i> - For matched studies, give matching criteria and the number of controls per case</p>		<p>algorithms used to identify subjects) should be listed in detail. If this is not possible, an explanation should be provided.</p> <p>RECORD 6.2: Any validation studies of the codes or algorithms used to select the population should be referenced. If validation was conducted for this study and not published elsewhere, detailed methods and results should be provided.</p> <p>RECORD 6.3: If the study involved linkage of databases, consider use of a flow diagram or other graphical display to demonstrate the data linkage process, including the number of individuals with linked data at each stage.</p>	<p>NA, used standard clinical codes</p> <p>Figure 1</p>
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.		RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided. If these cannot be reported, an explanation should be provided.	Methods p. 7-9 [calculated odds ratios]
Data sources/ measurement	8	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group			Methods p. 7-9 Read codes in GP data ICD-10 codes in PEDW data
Bias	9	Describe any efforts to address potential sources of bias			Methods p. 7-9 Case-control comparison only

					for years and GP practices with good data coverage
Study size	10	Explain how the study size was arrived at			Methods p. 7-9 Combined first diagnoses in GP and PEDW
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why			Methods p. 7-9
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) <i>Cohort study</i> - If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> - If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> - If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses			Methods p. 7-9 a) Simple odds ratios b) Simple counts c) NA (based on diagnoses) d) Cohort – NA Case-control: week of birth and gender, dependant on registration with GP e) NA
Data access and cleaning methods		..		RECORD 12.1: Authors should describe the extent to which the investigators had access to the database population used to create the study	Methods p 7-9

				population. RECORD 12.2: Authors should provide information on the data cleaning methods used in the study.	Methods p. 7-9
Linkage		..		RECORD 12.3: State whether the study included person-level, institutional-level, or other data linkage across two or more databases. The methods of linkage and methods of linkage quality evaluation should be provided.	Methods p. 7-9
Results					
Participants	13	(a) Report the numbers of individuals at each stage of the study (<i>e.g.</i> , numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed) (b) Give reasons for non-participation at each stage. (c) Consider use of a flow diagram		RECORD 13.1: Describe in detail the selection of the persons included in the study (<i>i.e.</i> , study population selection) including filtering based on data quality, data availability and linkage. The selection of included persons can be described in the text and/or by means of the study flow diagram.	Results p. 9-12 Figure 1
Descriptive data	14	(a) Give characteristics of study participants (<i>e.g.</i> , demographic, clinical, social) and information on exposures and potential confounders (b) Indicate the number of participants with missing data for each variable of interest (c) <i>Cohort study</i> - summarise follow-up time (<i>e.g.</i> , average and total amount)			a) p. 9-12 b) only exact matches, cannot identify missing data c) NA
Outcome data	15	<i>Cohort study</i> - Report numbers of outcome events or summary measures over time <i>Case-control study</i> - Report			p. 9-12 cohort: total number of people diagnosed in

		numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> - Report numbers of outcome events or summary measures			either GP or PEDW case-control: odds ratios
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period			p. 9-12 a) Simple odds ratios b) Based on Read chapters c) NA
Other analyses	17	Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses			Young people vs. adults Results p. 11
Discussion					
Key results	18	Summarise key results with reference to study objectives			p. 12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias		RECORD 19.1: Discuss the implications of using data that were not created or collected to answer the specific research question(s). Include discussion of misclassification bias, unmeasured confounding, missing data, and changing eligibility over time, as they pertain to the study being reported.	p. 12-13
Interpretation	20	Give a cautious overall interpretation of results considering objectives,			p. 12-13

		limitations, multiplicity of analyses, results from similar studies, and other relevant evidence			
Generalisability	21	Discuss the generalisability (external validity) of the study results			Discussion p. 12
Other Information					
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based			p. 14
Accessibility of protocol, raw data, and programming code		..		RECORD 22.1: Authors should provide information on how to access any supplemental information such as the study protocol, raw data, or programming code.	p. 16 data sharing statement

*Reference: Benchimol EI, Smeeth L, Guttman A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langhin SM, the RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. *PLoS Medicine* 2015; in press.

*Checklist is protected under Creative Commons Attribution ([CC BY](https://creativecommons.org/licenses/by/4.0/)) license.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

BMJ Open

Diagnosed prevalence of Ehlers-Danlos syndrome and Hypermobility Spectrum Disorder in Wales, UK: a national electronic cohort study and case-control comparison

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-031365.R1
Article Type:	Original research
Date Submitted by the Author:	23-Jul-2019
Complete List of Authors:	Demmler, Joanne; Swansea University, Swansea University Medical School Atkinson, Mark; Swansea University, Swansea University Medical School Reinhold, Emma; Royal College of General Practitioners Choy, Ernest; Cardiff University, School of Medicine Lyons, Ronan; Swansea University, Swansea University Medical School Brophy, Sinead; Swansea University, Swansea University Medical School
Primary Subject Heading:	Public health
Secondary Subject Heading:	General practice / Family practice, Health informatics
Keywords:	Heritable Disorders of Connective Tissue, Ehlers-Danlos Syndromes, Joint Hypermobility Syndrome, Hypermobility Spectrum Disorder, Health Data Linkage, Prevalence

SCHOLARONE™
Manuscripts

1
2
3 **Diagnosed prevalence of Ehlers-Danlos syndrome and Hypermobility Spectrum**
4 **Disorder in Wales, UK: a national electronic cohort study and case-control**
5 **comparison**
6
7
8
9

10
11 Joanne C Demmler, Mark D Atkinson, Emma J Reinhold, Ernest Choy, Ronan A Lyons,
12 Sinead T Brophy
13

14
15
16
17
18 Joanne C Demmler, Lecturer, Health Data Research UK, Swansea University, Singleton
19 Park, Swansea SA2 8PP, UK. j.demmler@swansea.ac.uk.

20
21
22
23 Mark D Atkinson, Research Officer, Secure Anonymised Information Linkage (SAIL)
24 Databank, Swansea University, Singleton Park, Swansea SA2 8PP, UK.
25
26
27 m.atkinson@swansea.ac.uk.

28
29
30 Emma J Reinhold, RCGP Clinical Champion for the Ehlers-Danlos Syndromes, Clinical
31 Innovation and Research Centre, Royal College of General Practitioners, 30 Euston Square,
32 London, NW1 2FB. e.reinhold@doctors.org.uk.

33
34
35 Ernest Choy, Professor, Arthritis Research UK CREATE Centre, Section of Rheumatology,
36 Division of Infection and Immunity, Cardiff University, Cardiff CF14 4YS, UK.
37
38
39
40
41 ChoyEH@cardiff.ac.uk.

42
43
44 Ronan A Lyons, Professor, Health Data Research UK, Swansea University, Singleton Park,
45 Swansea SA2 8PP, UK. r.a.lyons@swansea.ac.uk.

46
47
48
49 Sinead T Brophy, Professor, Health Data Research UK, Swansea University, Singleton Park,
50 Swansea SA2 8PP, UK. s.brophy@swansea.ac.uk.

51
52
53
54
55
56 Correspondence to: JC Demmler j.demmler@swansea.ac.uk. Tel: 44 (0) 1792 295674
57
58
59
60

Abstract

Objectives: To describe the epidemiology of diagnosed Hypermobility Spectrum Disorder (HSD) and Ehlers-Danlos Syndromes (EDS) using linked electronic medical records. To examine whether these conditions remain rare and primarily affect the musculoskeletal system.

Design: Nationwide linked electronic cohort and nested case-control study

Setting: Routinely collected data from primary care and hospital admissions in Wales, UK.

Participants: People within the primary care or hospital data systems with a coded diagnosis of Ehlers-Danlos syndrome (EDS) or Joint Hypermobility Syndrome (JHS) between 01/07/1990 and 30/06/2017.

Main outcome measures: Combined prevalence of JHS and EDS in Wales. Additional diagnosis and prescription data in those diagnosed with EDS or JHS compared with matched controls.

Results: We found 6,021 individuals (male: 30%, female: 70%) with a diagnostic code of either EDS or JHS. This gives a diagnosed point prevalence of 194.2 per 100,000 in 2016/17 or roughly 10 cases in a practice of 5000 patients. There was a pronounced gender difference of 8.5 years (95% CI: 7.70 to 9.22) in the mean age at diagnosis. EDS or JHS was not only associated with high odds for other musculoskeletal diagnoses and drug prescriptions, but also with significantly higher odds of a diagnosis in other disease categories (e.g. mental health, nervous and digestive systems) and higher odds of a prescription in most disease categories (e.g. gastro-intestinal and cardiovascular drugs) within the 12 months before and after the first recorded diagnosis.

Conclusions: EDS and JHS (since March 2017 classified as EDS or HSD) have historically been considered rare diseases only affecting the musculoskeletal system and soft tissues. These data demonstrate that both of these assertions should be reconsidered.

1
2
3
4
5
6 **Key Words:** Heritable Disorders of Connective Tissue, Ehlers-Danlos Syndromes, Joint
7
8 Hypermobility Syndrome, Hypermobility Spectrum Disorder, Health Data Linkage,
9
10 Prevalence
11
12

13 **Word Count:** 3687
14
15
16
17
18

19 **Strengths and Limitations**

- 22 • Large cohort and nested case-control studies based on whole population routinely
23 collected health data from primary and secondary care
- 26 • We are unable to quantify how many people are suffering from hypermobile EDS
27 (hEDS) or HSD but remain undiagnosed, nor can we make any statement on the
28 reliability of the diagnoses
- 32 • Although we only compared codes at Read chapter level all diagnoses and
33 prescriptions can be matched to conditions found in the EDS/JHS literature
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

The Ehlers-Danlos Syndromes (EDS) are a group of hereditary connective tissue disorders which mainly affect collagen. The nomenclature of these conditions has undergone a number of iterations which makes discussion of their prevalence complicated (see Textbox 1).

For many decades, studies have quoted a prevalence rate of 1 in 5000 for EDS, although the origin of this figure is unclear, seeming to appear first in a medical textbook^{1 2} as an unreferenced “reasonable estimate”. Thus, these syndromes have long been categorised as rare diseases, defined in the European Union as those affecting fewer than 50 in 100,000 people³. Kulas Søbørg et al.⁴ recently reported a prevalence of 20 per 100,000 for EDS in a nationwide Danish cohort based on secondary health care data up to 2012, but importantly, this data did not include patients who had received the considerably more common JHS diagnosis, now included in the latest revised classification. It is possible to extrapolate a combined population prevalence figure for JHS and EDS for Sweden⁵ of around 120 per 100,000 from a study focussing on comorbid mental health issues, but no investigators have thus far set out to investigate the combined diagnosed prevalence of JHS/EDS within a population.

Although common features of these conditions are arthralgia, soft tissue injury and joint instability⁶, over the last two decades it has become clear that their clinical features are not limited to musculoskeletal and cutaneous involvement, but are multisystemic⁷⁻⁹. In the special edition of the American Journal of Medical Genetics dedicated to EDS in March 2017, papers covered links to cardiovascular autonomic¹⁰ and gastrointestinal dysfunction¹¹ as well as psychiatric and neurodevelopmental disorders^{5 12}. Chronic disabling fatigue¹³ and pain syndromes¹⁴ were also recognised as common and multifactorial issues. Gynaecological^{15 16} and obstetric¹⁷ issues are also reported in this population. There is also an emerging link with the potentially life-threatening condition of Mast Cell Activation

1
2
3 Syndrome^{18 19}. There is some emerging evidence hinting that nutritional deficiencies^{20 21}
4 may play a key role, both seeming to be more prevalent in these patients and possibly
5 implicated in the development of some of the complications.
6
7
8

9
10 Early diagnosis is found to be crucial to patients²² to enable the provision of appropriate
11 treatment, as well as to prevent later onset complications⁷. Establishing the diagnosis of
12 EDS/HSD is often problematic for patients, which interferes with the early detection,
13 treatment and prevention of further escalations of recognised symptoms, disability and more
14 elaborate complications. A mean of 14 years elapses between the first clinical
15 manifestations and the actual diagnosis²³. For 25% of patients this delay lasts over 28 years
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
23. "A misdiagnosis was given to 56% of patients [resulting in] inappropriate treatment in 70%
of the patients... For 86% of the patients, the delay in diagnosis was considered responsible
for deleterious consequences." ^{23(p.137)}

It is possible that some of these difficulties arise from the widespread belief amongst
clinicians that EDS is rare. It is therefore of clinical importance to establish better estimates
of current prevalence. Conventional studies tend to be based in restricted clinical settings,
such as rheumatology clinics, and are therefore limited by the number of recruited patients
and biased by severity/type of patients referred. It has been shown that using linked health
data is an economic and effective alternative to performing *de novo* longitudinal studies,
including rare conditions^{24 25}. We used routinely held data from primary and secondary care
sources to examine the epidemiology of people with a diagnostic code for EDS/JHS in
Wales. We then conducted a nested case- control study to study the number of diagnoses
across all body/disease systems and prescription usage in order to test the widespread
belief that these conditions are primarily musculoskeletal in nature, rather than multi-system
disorders.

Methods

Study design: Nationwide electronic cohort study

Anonymised record linkage and hosting is carried out in the Secure Anonymised Information Linkage (SAIL) databank²⁶ on routinely collected data held in health and social care datasets. All data within the SAIL gateway are treated in accordance with the Data Protection Act 2018 and complies with GDPR.

We used data from a variety of datasets between 01/07/1990 and 30/06/2017 to create the anonymised e-cohort and case control studies. The Primary Care data covers about 80% of all coded information held by General Practitioners (GPs) in Wales. The Welsh Demographics Service (WDS) contains key statistics, such as gender, week of birth, date of death and practice migration status for everyone in Wales registered with a GP. The Patient Episode Database for Wales (PEDW) contains all inpatient hospital admissions to a Welsh hospital. WDS and PEDW data are available for the whole of Wales. The SAIL databank enables the anonymised matching of individuals across these different datasets using a person level anonymised linkage field (ALF)²⁶.

Cohort preparation

We identified Welsh residents with a Read Version 2²⁷ diagnostic code of EDS or JHS in primary care data or ICD-10 diagnostic codes²⁸ in secondary care data (hospital admissions) between 01/07/1990 (or the start of the dataset if later) and 30/06/2017. This date marks the end of maximum data coverage across all datasets. The EDS sub-classification in Read Version 2 contains some, but not all, of the subtypes which were in use prior to 1997 and as a result, the reliability of any subtype data must be highly questionable (see Table 1). Due to the lack of available correct sub-codes for EDS subtypes, the fact that the overwhelming majority of patients simply had the header code (86% of those coded as EDS, with a further 12% coded as hEDS), and that other EDS types are genuinely rare, all codes for EDS were combined. ICD-10 codes do not distinguish between any subtypes of EDS (see Table 1). Only ALF's with good matching status were included in the

1
2
3 study, i.e. direct match on either NHS number or on surname, first name, postcode, date of
4 birth and gender; or fuzzy matching with a probability of $\geq 90\%$.
5
6

7
8 We created one dataset for diagnoses in the GP data and another for diagnoses in the
9 hospital data. Both datasets were linked to the week of birth, gender and date of death
10 information in WDS on their ALF and then combined to create a cohort of people with
11 EDS/JHS in either GP or hospital data, identifying any duplications and keeping the earliest
12 diagnosis date for any individual appearing in both datasets.
13
14
15
16
17

18 19 **Analysis**

20
21 Data linkage and data preparation within the SAIL databank were conducted using IBM DB2
22 10.5 SQL. Data were then imported into R (Version 3.4.1)²⁹, which was used for all
23 statistical analyses. The mean age at first diagnosis between male and female subjects was
24 compared and confidence intervals of the difference calculated.
25
26
27
28
29

30
31 The denominator of the diagnosed prevalence and incidence of EDS and JHS in secondary
32 care was calculated based on the total number of individuals with recorded gender,
33 registered and living in Wales between 01/07/1990 and 30/06/2017 for each full year of the
34 study respectively. The prevalence and incidence in primary care denominator was further
35 adjusted to include only people living in Wales and whose GP practice was contributing data
36 to SAIL. The prevalence and incidence in primary and secondary care was then added
37 together to create an overall estimate of the prevalence and incidence in Wales.
38
39
40
41
42
43
44
45

46 47 **Case-Control Comparison**

48
49 A nested case control method was used. Each case was matched to 4 controls with the
50 same gender and similar age profiles (within 45 days of the week of birth). We implemented
51 strict criteria for selection to the case-control cohort. Both cases and controls had to (a) have
52 uninterrupted GP registrations for 1 year before and 1 year after the date of the relevant
53 diagnosis (or died during follow-up); (b) be registered with a GP submitting data to SAIL
54 either at the matching date or afterwards; (c) have been registered with a GP that
55
56
57
58
59
60

1
2
3 consistently recorded data across their patient profile. The latter avoids diagnoses that were
4 retrospectively entered for a time period when the GP practice did not fully implement the
5 use of electronic records (less than 10% of the data they recorded during 2009). Although
6 this reduced the number of cases and controls we were able to analyse, it avoids data
7 quality bias, especially during the early years of this study, when GPs were converting to the
8 use of computer systems and databases. Controls with any type of diagnosed hereditary
9 connective tissue disorder were excluded. Preliminary analysis of the combined cohort
10 indicated that adjustment for deprivation was not necessary (i.e. equal distribution of people
11 across deprivation quintiles). We then calculated odds ratios between cases and controls
12 using Read chapters (excluding the Read codes for EDS and JHS). All results that affected
13 at least 5 cases or 20 controls were visualised using forest plots.
14
15
16
17
18
19
20
21
22
23
24
25
26

27 **Ethical approval**

28
29 The study design uses anonymised data and therefore the need for ethical approval and
30 participant consent was waived by the approving Institutional Review Board, the UK National
31 Health Service Research Ethics Committee. The SAIL independent Information Governance
32 Review Panel (IGRP) approved the study.
33
34
35
36
37
38

39 **Patient and Public Involvement**

40
41 Two of the authors of this paper have been diagnosed with symptomatic joint hypermobility
42 disorders. This study used routinely collected data, we were not able to involve members of
43 the public but will be disseminating our findings widely, including directly to patients via
44 social media and through our links with patient organisations.
45
46
47
48
49
50

51 **Results**

52 **EDS/JHS in Primary Care data**

53
54
55
56
57 5,355 individuals with a diagnosis of either EDS or JHS with valid birth and gender
58 information were identified. Of these, 4,654 (87%) had a diagnosis of JHS and 701 (13%) of
59
60

1
2
3 EDS. The Read code for the EDS subtype was only used for 136 (19%) individuals with 114
4 (16%) identified as EDS-Hypermobility Type and 22 (3%) as other EDS subtypes. 3,759
5 (70%) of those diagnosed with EDS/JHS were female (see Figure 1).
6
7
8
9

10 **EDS/JHS in Hospital Data**

11
12
13 A total of 1,298 individuals were found in the hospital data of whom 970 (75%) were female:
14
15 745 (57%) had a diagnosis of JHS and 553 (43%) EDS (see Figure 1).
16
17

18 **Demographics of combined EDS/JHS cohort**

19
20 5,355 (89%) of the cases could be found in the primary care data with the remainder in the
21 hospital cohort. Combining the results from primary and secondary care led to a cohort of
22
23 6,021 distinct individuals. 5,064 (84%) were coded with JHS and 957 (16%) with EDS. 4,244
24 (70%) of patients were female. The age at first diagnosis peaked in the age group 5-9 years
25 for males and 15-19 years for females (see Figure 2). There was a significant difference of
26
27 8.5 years in the mean age of diagnosis between males and females (95% CI: 7.70 to 9.22):
28
29 9.6 years in EDS (95% CI: 6.85 to 12.31) and 8.3 years in JHS (95% CI: 7.58 to 9.11). 72%
30 of males were diagnosed during childhood (age < 18 years) in contrast to only 41% of
31 females.
32
33
34
35
36
37
38
39

40 2016/17 is the latest year for which we have complete data and could therefore derive
41 prevalence. During this year, 2,668,902 people were registered with a GP in Wales
42 submitting data to SAIL, of whom 4,598 had a diagnostic code of EDS/JHS which first
43 appeared in the primary care data (172 in 100,000). A further 711 people out of the
44 3,239,153 registered with any GP in Wales during 2016/17 had an EDS/JHS diagnosis
45 which first appears in secondary care data (22 in 100,000). There is an increasing rate of
46 coded diagnoses throughout the period. Assuming that the GP data is representative of the
47 whole of Wales this leads to a combined point prevalence of 194 in 100,000 at the end of the
48 study period. This corresponds to about 10 cases in a practice of 5000 patients (see Figure
49 3). The incidence of EDS/JHS over this time period is shown in Supplement Figure 1.
50
51
52
53
54
55
56
57
58
59
60

Factors associated with JHS/EDS

2,597 cases had good GP data coverage at the age of diagnosis and could be matched by age and gender with controls (see Figure 1). 1,340 cases (male: 561; female: 779) were first diagnosed before the age of 18 years and 1,254 cases (male: 229; female: 1,025) above this age. The people in the nested case-control cohort were slightly older than the overall cohort (data not shown here).

Looking at the time frame of 1 year either side of the first coded diagnosis of EDS/JHS amongst young people (age < 18 years) there were significantly more additional diagnoses in 16 out of 20 Read code disease categories compared with their controls (see Figure 4a). The top three Read diagnosis chapters with increased odds for the EDS/JHS cohort were for musculoskeletal conditions (OR 9.36, 95% CI: 7.98 to 11.00), congenital anomalies (OR 5.89; 95% CI: 3.98 to 8.80) and mental disorders (OR 4.16; 95% CI: 3.29 to 5.27).

People that were diagnosed as adults (age \geq 18 years) had also significantly more diagnoses in 16 out of 20 Read code categories than their controls (see Figure 4b). The top three Read diagnosis chapters for adults with higher odds in the EDS/JHS cohort were musculoskeletal disorders (OR 7.95; 95% CI: 6.95 to 9.12), congenital anomalies (OR 5.18; 95% CI: 2.78 to 9.78) and symptoms, signs and ill-defined conditions (OR 2.9; 95% CI: 2.5 to 3.37). Circulatory system disease (OR 2.29; 95% CI: 1.83 to 2.86) and mental disorders remained significant (OR 1.87; 95% CI: 1.57 to 2.22), but not to the same extent as they were for young people.

Young people showed significantly higher odds for prescriptions in 14 out of 17 Read code categories than their controls (see Figure 5a). The top three prescriptions Read chapters with increased odds for the EDS/JHS cohort were for (i) musculoskeletal drugs (OR 3.65; 95% CI: 3.18 to 4.18), (ii) gastro-intestinal drugs (OR 3.02; 95% CI: 2.54 to 3.58) and (iii) haematology/dietetic drugs (OR 2.54; 95% CI: 2.06 to 3.11).

1
2
3 Adults had significantly higher odds of prescriptions for 15 out of 17 Read code categories
4 (see Figure 5b). The top three prescriptions with higher odds for EDS/JHS people were for
5 (i) musculoskeletal drugs (OR 5.17; 95% CI: 4.53 to 5.9), (ii) central nervous system drugs
6 (OR 3.9; 95% CI: 3.41 to 4.46) and (iii) chemotherapy/immunosuppressant drugs (OR 3.03;
7 95% CI: 1.89 to 4.8). Gastro-intestinal drugs (OR 2.85; 95% CI: 2.5 to 3.24) and
8 haematology/dietetic drugs (OR 2.21; 95% CI: 1.9 to 2.57) remain significant, but at slightly
9 lower levels than in the young EDS/JHS population.
10
11
12
13
14
15
16
17

18 Discussion

19
20
21
22 This work examined the epidemiology of EDS and JHS and found a combined diagnosed
23 prevalence of 194.2 per 100,000 (0.19%), or 1 in 500 people in Wales; hEDS or HSD within
24 the 2017 classification. We found a steadily increasing rate of diagnosis over the past 27
25 years (see Supplement Figure 1), as well as higher rates of diagnoses for other conditions
26 and prescriptions within 12 months (pre and post) of the recorded first diagnosis in most
27 categories. This suggests that hEDS/HSD, when considered together, do not meet the
28 definition of rare conditions ²³, and have widespread effects across multiple body systems.
29
30
31
32
33
34
35

36 It is well-known that EDS is poorly recognised in children ^{30 31} and initial symptoms and EDS-
37 associated diagnoses can appear to be simply a 'normal' pattern of childhood illness when
38 taken as an isolated event. Furthermore, children with hEDS often present with symptoms
39 that can lead to a misdiagnosis of mental illness or consideration of child abuse ^{12 32}.
40
41
42
43
44

45 Suspicion of abuse has been shown to be extremely damaging to the mental health of the
46 parent(s) and can lead to an avoidance of accessing health care or other public services,
47 such as schools ³³. The prolonged and sometimes traumatic diagnosis and/or misdiagnosis
48 process in EDS can lead to further disengagement with services ³⁴. The lack of a timely
49 diagnosis has great implications for disease management and progression and impedes the
50 appropriate consideration of surgical interventions ^{7 35-38} as well as pregnancy and birth
51 planning ¹⁷. It is perhaps only in stepping back to look at the pattern of effects across
52
53
54
55
56
57
58
59
60

1
2
3 multiple body systems that practitioners might begin to consider a connective tissue
4
5 disorder.
6
7

8 **Strengths and Limitations**

9

10 The strength of this study is that we were able to combine diagnostic codes from several
11 primary and secondary health care providers to create a large cohort of individuals with
12 EDS/JHS. We have 27 years of data with at least 11 years of very good data coverage in the
13 key datasets, which further improves with each data update of the SAIL databank, however
14 data coverage for the first couple of years is less comprehensive.
15
16
17
18
19
20
21

22 The majority of subjects were identified via their primary care data, which is a strength and a
23 weakness. As 89% of cases were identified through primary care data studies not using
24 primary care data may underestimate the prevalence of hEDS/HSD. We are unable to
25 quantify how many people are suffering from hEDS or HSD but remain undiagnosed.
26
27
28
29
30 However, we cannot comment on the reliability of the diagnoses in the primary care dataset.
31
32 It is also likely that the majority of cases were not actually diagnosed in primary care, but
33 their entries were created through secondary care contacts, such as outpatient appointments
34 or musculoskeletal assessment clinics, but coded data are lacking from these sources.
35
36
37
38
39

40 Although a snapshot of Read chapters codes that are more prevalent in our JHS/EDS cohort
41 does not allow us to look at specific diagnoses and prescriptions, they can all be matched to
42 conditions associated with EDS/JHS in the literature, for instance pain, fatigue,
43 cardiovascular, gastrointestinal and gynaecological disorders, dysautonomia, mast cell
44 activation as well as urinary tract infections ⁷. We hope in future work to examine in greater
45 detail these findings of significant differences between people with hEDS/HSD and others in
46 order that we can better understand the nature of this condition, as well as potentially
47 improving diagnostic recognition. Having created this case-control cohort, further
48 examination is made simpler as this first step has already been made.
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 We conclude that EDS/HSD are not rare conditions and are associated with significantly
4 increased odds of additional diagnoses and use of medications across many body systems.
5
6 There is a large gender difference in the age of diagnosis, with many women not diagnosed
7
8 until adulthood. Early diagnosis, however, is crucial to patients, the administration of
9
10 preventive therapies, the investigation of comorbid conditions and the overall management
11
12 process. Further research is needed to understand patient pathways, comorbidities and
13
14 progression of associated symptoms and diseases. Health services should be aware of
15
16 these findings for the provision of training, diagnostic and treatment services for the many
17
18 tens of thousands of patients living with these life-changing conditions throughout the United
19
20 Kingdom and beyond.
21
22
23

24 25 **Author contributions**

26
27 JD conceived the project. SB and MA contributed to the study design and analysis plan. RAL
28
29 validated clinical codes in primary care. EC validated clinical codes in secondary care. JD
30
31 undertook the analysis. JD and ER carried out the literature reviews and drafted the
32
33 manuscript. All authors reviewed the manuscript and approved the final version for
34
35 submission.
36
37
38
39

40 41 **Funding**

42
43 This work was supported by The Farr Institute. The Farr Institute was supported by a 10-
44
45 funder consortium: Arthritis Research UK, the British Heart Foundation, Cancer Research
46
47 UK, the Economic and Social Research Council, the Engineering and Physical Sciences
48
49 Research Council, the Medical Research Council, the National Institute of Health Research,
50
51 the National Institute for Social Care and Health Research (Welsh Assembly Government),
52
53 the Chief Scientist Office (Scottish Government Health Directorates), the Wellcome Trust,
54
55 (MRC Grant No: MR/K006525/1).
56
57

58
59 This work was also supported by Health Data Research UK which receives its funding from
60
HDR UK Ltd (NIWA1) funded by the UK Medical Research Council, Engineering and

1
2
3 Physical Sciences Research Council, Economic and Social Research Council, Department
4 of Health and Social Care (England), Chief Scientist Office of the Scottish Government
5 Health and Social Care Directorates, Health and Social Care Research and Development
6 Division (Welsh Government), Public Health Agency (Northern Ireland), British Heart
7 Foundation (BHF) and the Wellcome Trust.
8
9
10
11
12

13
14 The above funders played no role in the study design, in the collection, analysis, or
15 interpretation of data; in the writing of the report; or in the decision to submit the article for
16 publication. The researchers are independent from the funders and all authors, external and
17 internal, had full access to all of the data in the study and take responsibility for the integrity
18 of the data and the accuracy of the data analysis.
19
20
21
22
23
24
25
26

27 Competing interests: All authors have completed the ICMJE uniform disclosure form at
28 www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the
29 submitted work; no financial relationships with any organisations that might have an interest
30 in the submitted work in the previous three years; no other relationships or activities that
31 could appear to have influenced the submitted work.
32
33
34
35
36
37
38
39

40 Exclusive licence: The Corresponding Author has the right to grant on behalf of all authors
41 and does grant on behalf of all authors, a worldwide licence
42 (<http://www.bmj.com/sites/default/files/BMJ%20Author%20Licence%20March%202013.doc>)
43 to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether
44 known now or created in the future), to i) publish, reproduce, distribute, display and store the
45 Contribution, ii) translate the Contribution into other languages, create adaptations, reprints,
46 include within collections and create summaries, extracts and/or, abstracts of the
47 Contribution and convert or allow conversion into any format including without limitation
48 audio, iii) create any other derivative work(s) based in whole or part on the on the
49 Contribution, iv) to exploit all subsidiary rights to exploit all subsidiary rights that currently
50
51
52
53
54
55
56
57
58
59
60

1
2
3 exist or as may exist in the future in the Contribution, v) the inclusion of electronic links from
4 the Contribution to third party material wherever it may be located; and, vi) licence any third
5 party to do any or all of the above. All research articles will be made available on an open
6 access basis (with authors being asked to pay an open access fee—see
7 [http://www.bmj.com/about-bmj/resources-authors/forms-policies-and-checklists/copyright-](http://www.bmj.com/about-bmj/resources-authors/forms-policies-and-checklists/copyright-open-access-and-permission-reuse)
8 open-access-and-permission-reuse). The terms of such open access shall be governed by a
9 Creative Commons licence—details as to which Creative Commons licence will apply to the
10 research article are set out in our worldwide licence referred to above.

11
12
13
14
15
16
17
18
19
20
21
22 Transparency declaration: The lead author affirms that this manuscript is an honest,
23 accurate, and transparent account of the study being reported; that no important aspects of
24 the study have been omitted; and that any discrepancies from the study as planned (and, if
25 relevant, registered) have been explained.

26
27
28
29
30
31
32
33 Dissemination statement: We are planning to disseminate our results to patient groups using
34 social media.

35
36
37
38
39 Data sharing statement: The data used in this study are available in the SAIL databank at
40 Swansea University, Swansea, UK. All proposals to use SAIL data are subject to review by
41 an independent Information Governance Review Panel (IGRP). Before any data can be
42 accessed, approval must be given by the IGRP.

43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
The IGRP gives careful consideration to each project to ensure proper and appropriate use
of SAIL data. When access has been granted, it is gained through a privacy-protecting safe
haven and remote access system referred to as the SAIL Gateway. SAIL has established an
application process to be followed by anyone who would like to access data via SAIL
<https://www.saildatabank.com/application-process>.

Additional resources: RCGP Clinical Toolkit on the Ehlers-Danlos Syndromes

www.rcgp.org.uk/eds; RCGP Podcast “Introduction to Ehlers-Danlos Syndromes”

<https://audioboom.com/posts/6896541-introduction-to-ehlers-danlos-syndromes>

References

1. Cecil RLF, Goldman L, Bennett JC. Cecil Textbook of Medicine: W.B. Saunders 2000.
2. Mulvey MR, Macfarlane GJ, Beasley M, et al. Modest Association of Joint Hypermobility With Disabling and Limiting Musculoskeletal Pain: Results From a Large-Scale General Population-Based Survey. *Arthritis Care & Research* 2013;65(8):1325-33. doi: 10.1002/acr.21979
3. Commission of the European Communities Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the regions on Rare Diseases: Europe's challenges. Brussels: Commission of the European Communities, 2008.
4. Søborg M-LK, Leganger J, Mortensen LQ, et al. Establishment and baseline characteristics of a nationwide Danish cohort of patients with Ehlers–Danlos syndrome. *Rheumatology (Oxford)* 2017;56(5):763-67. doi: 10.1093/rheumatology/kew478
5. Cederlöf M, Larsson H, Lichtenstein P, et al. Nationwide population-based cohort study of psychiatric disorders in individuals with Ehlers-Danlos syndrome or hypermobility syndrome and their siblings. *Bmc Psychiatry* 2016;16 doi: 10.1186/s12888-016-0922-6
6. Hakim AJ, Grahame R. A simple questionnaire to detect hypermobility: An adjunct to the assessment of patients with diffuse musculoskeletal pain. *International Journal of Clinical Practice* 2003;57(3):163-66.
7. Tinkle B, Castori M, Berglund B, et al. Hypermobility Ehlers-Danlos Syndrome (a.k.a. Ehlers-Danlos Syndrome Type III and Ehlers-Danlos Syndrome Hypermobility Type): Clinical Description and Natural History. *American Journal of Medical Genetics Part C-Seminars in Medical Genetics* 2017;175(1):48-69. doi: 10.1002/ajmg.c.31538
8. Gazit Y, Jacob G, Grahame R. Ehlers-Danlos Syndrome-Hypermobility Type: A Much Neglected Multisystemic Disorder. *Rambam Maimonides Medical Journal* 2016;7(4) doi: 10.5041/rmmj.10261
9. De Paepe A, Malfait F. The Ehlers-Danlos syndrome, a disorder with many faces. *Clinical Genetics* 2012;82(1):1-11. doi: 10.1111/j.1399-0004.2012.01858.x
10. Hakim A, O'Callaghan C, De Wandele I, et al. Cardiovascular Autonomic Dysfunction in Ehlers-Danlos Syndrome-Hypermobility Type. *American Journal of Medical Genetics Part C-Seminars in Medical Genetics* 2017;175(1):168-74. doi: 10.1002/ajmg.c.31543
11. Fikree A, Chelimsky G, Collins H, et al. Gastrointestinal Involvement in the Ehlers-Danlos Syndromes. *American Journal of Medical Genetics Part C-Seminars in Medical Genetics* 2017;175(1):181-87. doi: 10.1002/ajmg.c.31546
12. Bulbena A, Baeza-Velasco C, Bulbena-Cabre A, et al. Psychiatric and Psychological Aspects in the Ehlers-Danlos Syndromes. *American Journal of Medical Genetics Part C-Seminars in Medical Genetics* 2017;175(1):237-45. doi: 10.1002/ajmg.c.31544

13. Hakim A, De Wandele I, O'Callaghan C, et al. Chronic Fatigue in Ehlers-Danlos Syndrome-Hypermobility Type. *American Journal of Medical Genetics Part C-Seminars in Medical Genetics* 2017;175(1):175-80. doi: 10.1002/ajmg.c.31542
14. Chopra P, Tinkle B, Hamonet C, et al. Pain Management in the Ehlers-Danlos Syndromes. *American Journal of Medical Genetics Part C-Seminars in Medical Genetics* 2017;175(1):212-19. doi: 10.1002/ajmg.c.31554
15. Veit-Rubin N, Cartwright R, Singh AU, et al. Association between joint hypermobility and pelvic organ prolapse in women: a systematic review and meta-analysis. *International Urogynecology Journal* 2016;27(10):1469-78. doi: 10.1007/s00192-015-2896-1
16. Hugon-Rodin J, Lebegue G, Becourt S, et al. Gynecologic symptoms and the influence on reproductive life in 386 women with hypermobility type ehlers-danlos syndrome: a cohort study. *Orphanet Journal of Rare Diseases* 2016;11 doi: 10.1186/s13023-016-0511-2
17. Pezaro S, Pearce G, Reinhold E. Hypermobility Ehlers-Danlos Syndrome during pregnancy, birth and beyond. *British Journal of Midwifery* 2018;26(4):217-23. doi: 10.12968/bjom.2018.26.4.217
18. Seneviratne SL, Maitland A, Afrin L. Mast Cell Disorders in Ehlers-Danlos Syndrome. *American Journal of Medical Genetics Part C-Seminars in Medical Genetics* 2017;175(1):226-36. doi: 10.1002/ajmg.c.31555
19. Cheung I, Vadas P. A New Disease Cluster: Mast Cell Activation Syndrome, Postural Orthostatic Tachycardia Syndrome, and Ehlers-Danlos Syndrome. *Journal of Allergy and Clinical Immunology* 2015;135(2):AB65-AB65.
20. Mantle D, Wilkins RM, Preedy V. A novel therapeutic strategy for Ehlers-Danlos syndrome based on nutritional supplements. *Medical Hypotheses* 2005;64(2):279-83. doi: 10.1016/j.mehy.2004.07.023
21. Castori M, Morlino S, Pascolini G, et al. Gastrointestinal and Nutritional Issues in Joint Hypermobility Syndrome/Ehlers-Danlos Syndrome, Hypermobility Type. *American Journal of Medical Genetics Part C-Seminars in Medical Genetics* 2015;169(1):54-75. doi: 10.1002/ajmg.c.31431
22. Terry RH, Palmer ST, Rimes KA, et al. Living with joint hypermobility syndrome: patient experiences of diagnosis, referral and self-care. *Family Practice* 2015;32(3):354-58. doi: 10.1093/fampra/cmz026
23. EURORDIS AKFF. The Voice of 12,000 Patients. Experiences and Expectations of Rare Disease Patients on Diagnosis and Care in Europe: Eurordis 2009.
24. Holman CDJ, Bass AJ, Rosman DL, et al. A decade of data linkage in Western Australia: strategic design, applications and benefits of the WA data linkage system. *Australian Health Review* 2008;32(4):766-77.
25. Cooksey R, Husain MJ, Brophy S, et al. The Cost of Ankylosing Spondylitis in the UK Using Linked Routine and Patient-Reported Survey Data. *Plos One* 2015;10(7) doi: 10.1371/journal.pone.0126105
26. Lyons RA, Jones KH, John G, et al. The SAIL databank: linking multiple health and social care datasets. *Bmc Medical Informatics and Decision Making* 2009;9 doi: 10.1186/1472-6947-9-3
27. Chisholm J. The READ Clinical Classification. *Brit Med J* 1990;300(6732):1092-92.
28. World Health Organization. ICD-10: International statistical classification of diseases and related health problems: World Health Organization 2016.
29. R: A Language and Environment for Statistical Computing [program]. Vienna, Austria: R Foundation for Statistical Computing, 2017.
30. Adib N, Davies K, Grahame R, et al. Joint hypermobility syndrome in childhood. A not so benign multisystem disorder? *Rheumatology* 2005;44(6):744-50. doi: 10.1093/rheumatology/keh557
31. Grahame R, Hakim AJ. Joint Hypermobility Syndrome is highly prevalent in general rheumatology clinics, its occurrence and clinical presentation being gender, age and race-related. *Annals of the Rheumatic Diseases* 2006;65:263-63.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
32. Castori M. Ehlers-Danlos Syndrome(s) Mimicking Child Abuse: Is There an Impact on Clinical Practice? (vol 169, pg 289, 2015). *American Journal of Medical Genetics Part A* 2016;170(7):1947-47. doi: 10.1002/ajmg.a.37733
33. Association for Improvements in Maternity Services (AIMS). The Child Protection System in England: Written evidence submitted by the Association for Improvements in the Maternity Services (AIMS) 2011 [Available from: <http://www.publications.parliament.uk/pa/cm201012/cmselect/cmeduc/writev/1514/cp29.htm> accessed 14/02/2019.
34. Berglund B, Anne-Cathrine M, Randers I. Dignity not fully upheld when seeking health care: Experiences expressed by individuals suffering from Ehlers–Danlos syndrome. *Disability and Rehabilitation* 2010;32(1):1-7. doi: 10.3109/09638280903178407
35. Schepers MC, Nicholson LL, Adams RD, et al. The natural history of children with joint hypermobility syndrome and Ehlers-Danlos hypermobility type: a longitudinal cohort study. *Rheumatology* 2017;56(12):2073-83. doi: 10.1093/rheumatology/kex148
36. Engelbert RHH, Juul-Kristensen B, Pacey V, et al. The Evidence-Based Rationale for Physical Therapy Treatment of Children, Adolescents, and Adults Diagnosed With Joint Hypermobility Syndrome/Hypermobility Ehlers Danlos Syndrome. *American Journal of Medical Genetics Part C-Seminars in Medical Genetics* 2017;175(1):158-67. doi: 10.1002/ajmg.c.31545
37. Ericson WB, Wolman R. Orthopaedic Management of the Ehlers-Danlos Syndromes. *American Journal of Medical Genetics Part C-Seminars in Medical Genetics* 2017;175(1):188-94. doi: 10.1002/ajmg.c.31551
38. Soborg MLK, Leganger J, Rosenberg J, et al. Increased Need for Gastrointestinal Surgery and Increased Risk of Surgery-Related Complications in Patients with Ehlers-Danlos Syndrome: A Systematic Review. *Digestive Surgery* 2017;34(2):161-70. doi: 10.1159/000449106
39. Sobey G. Ehlers-Danlos syndrome: how to diagnose and when to perform genetic tests. *Archives of Disease in Childhood* 2015;100(1):57-61. doi: 10.1136/archdischild-2013-304822
40. Grahame R, Bird HA, Child A, et al. The revised (Brighton 1998) criteria for the diagnosis of benign joint hypermobility syndrome (BJHS). *Journal of Rheumatology* 2000;27(7):1777-79.
41. Beighton P, De Paepe A, Steinmann B, et al. Ehlers-Danlos syndromes: Revised nosology, Villefranche, 1997. *American Journal of Medical Genetics* 1998;77(1):31-37. doi: 10.1002/(sici)1096-8628(19980428)77:1<31::aid-ajmg8>3.0.co;2-o
42. Grahame R. Joint hypermobility and genetic collagen disorders: are they related? *Archives of Disease in Childhood* 1999;80(2):188-91.
43. Malfait F, Francomano C, Byers P, et al. The 2017 International Classification of the Ehlers-Danlos Syndromes. *American Journal of Medical Genetics Part C-Seminars in Medical Genetics* 2017;175(1):8-26. doi: 10.1002/ajmg.c.31552
44. Castori M, Dordoni C, Morlino S, et al. Spectrum of Mucocutaneous Manifestations in 277 Patients with Joint Hypermobility Syndrome/Ehlers-Danlos Syndrome, Hypermobility Type. *American Journal of Medical Genetics Part C-Seminars in Medical Genetics* 2015;169(1):43-53. doi: 10.1002/ajmg.c.31425

Table 1: Clinical coding for Ehlers-Danlos Syndromes and Joint Hypermobility Syndrome.

Read code descriptions (based on pre-1997 nomenclature)	EDS type according to the Villefranche Criteria	EDS Type according to the March 2017 Criteria	Read code version 2	ICD10 code
Ehlers-Danlos syndrome			PGy2.	Q79.6
Ehlers-Danlos syndrome type I	Classical type	Classical EDS	PGy20	
Ehlers-Danlos syndrome type II			PGy21	
Ehlers-Danlos syndrome type III	Hypermobility type	Hypermobile EDS or Hypermobility Spectrum Disorder	PGy22	
Ehlers-Danlos syndrome type IV	Vascular type	Vascular EDS	PGy23	
Ehlers-Danlos syndrome type V	X-linked type	No longer classified as EDS	PGy24	
Ehlers-Danlos syndrome type VI	Kyphoscoliotic type	Kyphoscoliotic EDS	PGy25	
Ehlers-Danlos syndrome type VII	Arthrochalasia type Dermatosparaxis type	Arthrochalasia EDS Dermatosparaxis EDS	PGy26	
Ehlers-Danlos syndrome type VIII	Periodontitis type	Periodontal EDS	PGy27	
Hypermobility Syndrome (JHS according to the Brighton Criteria)	(Hypermobility type)	Hypermobile EDS or Hypermobility Spectrum Disorder	N235.	728.5

Textbox 1

Ehlers Danlos Syndrome Nomenclature

- Joint hypermobility *per se* is reasonably common and thought to be present in around 10% of the general UK population ³⁹.
- The Brighton criteria were used to diagnose Joint Hypermobility Syndrome from 1998 ⁴⁰,
- The Villefranche criteria were applied to confirm EDS-Hypermobility Type from 1997 ⁴¹.
- Prior to the Villefranche criteria, the diagnosis EDS III was used to denote the hypermobile subtype of EDS.
- It was recognised over a number of years that JHS and EDS-HT were not distinct from one another ⁴².
- In March 2017 the International Consortium on the Ehlers Danlos Syndromes published a revised classification ⁴³ naming two syndromes:
 - Hypermobile EDS (hEDS) which has narrowly defined criteria
 - Hypermobility Spectrum Disorder (HSD) for those with some but not all of the features of hEDS
- Patients who have a diagnosis of EDS-HT or JHS will fall into one of these two new categories.
- Castori et al showed that patients may move from the HSD category into hEDS over time: they also emphasised that the approach to management and the prognosis in terms of disability are the same ⁴⁴. One may therefore conclude that health needs across these groups are similar.

Figures

Figure 1: Flow diagram of EDS/JHS cohort and case-control cohort creation. Figure 2: Age at first coded diagnosis of EDS/JHS by age group and gender.

Figure 3: Prevalence of coded diagnosis of JHS/EDS in Primary Care, hospital inpatient and combined over time.

Figure 4: Odds ratios of Read chapter diagnoses for (a) young people (<18 years of age) and (b) adults (>= 18 years of age) within 12 months before and after EDS/JHS diagnosis.

Presented are all results that affect at least 5 cases or 20 controls (perinatal conditions,


1
2
3 chapter Q, are not shown as neither young people nor adults had the required minimum
4
5 number of cases/controls).
6
7

8 Figure 5: Odds ratios of Read chapter prescriptions for young people (<18 years of age) and
9
10 adults (≥ 18 years of age) within 12 months before and after EDS/JHS diagnosis.

11
12 Presented are all results that affect at least 5 cases or 20 controls (incontinence and stoma
13
14 appliances, chapters q and s, are not shown as neither young people nor adults had the
15
16 required minimum number of cases/results).
17
18


19 **Supplement Figures**

20
21
22 Supplement Figure 1: Incidence of diagnosis of JHS/EDS in GP, hospital inpatient and
23
24 combined data over time.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Flow diagram of EDS/JHS cohort and case-control cohort creation


209x297mm (300 x 300 DPI)



Age at first coded diagnosis of EDS/JHS by age group and gender


177x152mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Prevalence of coded diagnosis of JHS/EDS in Primary Care, hospital inpatient and combined over time

177x152mm (300 x 300 DPI)



Odds ratios of Read chapter diagnoses for (a) young people (<18 years of age) and (b) adults (≥ 18 years of age) within 12 months before and after EDS/JHS diagnosis. Presented are all results that affect at least 5 cases or 20 controls (perinatal conditions, chapter Q, are not shown as neither young people nor adults had the required minimum number of cases/controls)


177x127mm (300 x 300 DPI)



Odds ratios of Read chapter prescriptions for young people (<18 years of age) and adults (>= 18 years of age) within 12 months before and after EDS/JHS diagnosis. Presented are all results that affect at least 5 cases or 20 controls (incontinence and stoma appliances, chapters q and s, are not shown as neither young people nor adults had the required minimum number of cases/results)

177x127mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



177x152mm (300 x 300 DPI)

The RECORD statement – checklist of items, extended from the STROBE statement, that should be reported in observational studies using routinely collected health data.

	Item No.	STROBE items	Location in manuscript where items are reported	RECORD items	Location in manuscript where items are reported
Title and abstract					
	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found	Title and abstract	RECORD 1.1: The type of data used should be specified in the title or abstract. When possible, the name of the databases used should be included. RECORD 1.2: If applicable the geographic region and timeframe within which the study took place should be reported in the title or abstract. RECORD 1.3: If linkage between databases was conducted for the study, this should be clearly stated in the title or abstract.	Abstract p. 2 Abstract p. 2 Abstract p. 2
Introduction					
Background rationale	2	Explain the scientific background and rationale for the investigation being reported			Introduction p. 5-6
Objectives	3	State specific objectives, including any prespecified hypotheses			Introduction p. 6
Methods					
Study Design	4	Present key elements of study design early in the paper			Methods p. 7-9
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection			Methods p. 7-9
Participants	6	(a) <i>Cohort study</i> - Give the eligibility criteria, and the		RECORD 6.1: The methods of study population selection (such as codes or	Methods p. 7-9 Table 1

36/bmjopen-2024-019031-365
Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

		<p>sources and methods of selection of participants. Describe methods of follow-up</p> <p><i>Case-control study</i> - Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls</p> <p><i>Cross-sectional study</i> - Give the eligibility criteria, and the sources and methods of selection of participants</p> <p>(b) <i>Cohort study</i> - For matched studies, give matching criteria and number of exposed and unexposed</p> <p><i>Case-control study</i> - For matched studies, give matching criteria and the number of controls per case</p>		<p>algorithms used to identify subjects) should be listed in detail. If this is not possible, an explanation should be provided.</p> <p>RECORD 6.2: Any validation studies of the codes or algorithms used to select the population should be referenced. If validation was conducted for this study and not published elsewhere, detailed methods and results should be provided.</p> <p>RECORD 6.3: If the study involved linkage of databases, consider use of a flow diagram or other graphical display to demonstrate the data linkage process, including the number of individuals with linked data at each stage.</p>	<p>NA, used standard clinical codes</p> <p>Figure 1</p>
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.		RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided. If these cannot be reported, an explanation should be provided.	Methods p. 7-9 [calculated odds ratios]
Data sources/ measurement	8	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group			Methods p. 7-9 Read codes in GP data ICD-10 codes in PEDW data
Bias	9	Describe any efforts to address potential sources of bias			Methods p. 7-9 Case-control comparison only

					for years and GP practices with good data coverage
Study size	10	Explain how the study size was arrived at			Methods p. 7-9 Combined first diagnoses in GP and PEDW
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why			Methods p. 7-9
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) <i>Cohort study</i> - If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> - If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> - If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses			Methods p. 7-9 a) Simple odds ratios b) Simple counts c) NA (based on diagnoses) d) Cohort – NA Case-control: week of birth and gender, dependant on registration with GP e) NA
Data access and cleaning methods		..		RECORD 12.1: Authors should describe the extent to which the investigators had access to the database population used to create the study	Methods p 7-9

36/bmjopen-2019-031365 on 4 November 2019. Downloaded from <http://bmjopen.bmj.com/> on April 19, 2024 by guest. Protected by copyright.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

36/bmjopen-2019-033365 on April 19, 2024 by guest. Protected by copyright.

				population. RECORD 12.2: Authors should provide information on the data cleaning methods used in the study.	Methods p. 7-9
Linkage		..		RECORD 12.3: State whether the study included person-level, institutional-level, or other data linkage across two or more databases. The methods of linkage and methods of linkage quality evaluation should be provided.	Methods p. 7-9
Results					
Participants	13	(a) Report the numbers of individuals at each stage of the study (<i>e.g.</i> , numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed) (b) Give reasons for non-participation at each stage. (c) Consider use of a flow diagram		RECORD 13.1: Describe in detail the selection of the persons included in the study (<i>i.e.</i> , study population selection) including filtering based on data quality, data availability and linkage. The selection of included persons can be described in the text and/or by means of the study flow diagram.	Results p. 9-12 Figure 1
Descriptive data	14	(a) Give characteristics of study participants (<i>e.g.</i> , demographic, clinical, social) and information on exposures and potential confounders (b) Indicate the number of participants with missing data for each variable of interest (c) <i>Cohort study</i> - summarise follow-up time (<i>e.g.</i> , average and total amount)			a) p. 9-12 b) only exact matches, cannot identify missing data c) NA
Outcome data	15	<i>Cohort study</i> - Report numbers of outcome events or summary measures over time <i>Case-control study</i> - Report			p. 9-12 cohort: total number of people diagnosed in

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

		numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> - Report numbers of outcome events or summary measures			either GP or PEDW case-control: odds ratios
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period			p. 9-12 a) Simple odds ratios b) Based on Read chapters c) NA
Other analyses	17	Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses			Young people vs. adults Results p. 11
Discussion					
Key results	18	Summarise key results with reference to study objectives			p. 12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias		RECORD 19.1: Discuss the implications of using data that were not created or collected to answer the specific research question(s). Include discussion of misclassification bias, unmeasured confounding, missing data, and changing eligibility over time, as they pertain to the study being reported.	p. 12-13
Interpretation	20	Give a cautious overall interpretation of results considering objectives,			p. 12-13

		limitations, multiplicity of analyses, results from similar studies, and other relevant evidence			
Generalisability	21	Discuss the generalisability (external validity) of the study results			Discussion p. 12
Other Information					
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based			p. 14
Accessibility of protocol, raw data, and programming code		..		RECORD 22.1: Authors should provide information on how to access any supplemental information such as the study protocol, raw data, or programming code.	p. 16 data sharing statement

*Reference: Benchimol EI, Smeeth L, Guttman A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langhin SM, the RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. *PLoS Medicine* 2015; in press.

*Checklist is protected under Creative Commons Attribution ([CC BY](https://creativecommons.org/licenses/by/4.0/)) license.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

BMJ Open

Diagnosed prevalence of Ehlers-Danlos syndrome and Hypermobility Spectrum Disorder in Wales, UK: a national electronic cohort study and case-control comparison

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-031365.R2
Article Type:	Original research
Date Submitted by the Author:	23-Sep-2019
Complete List of Authors:	Demmler, Joanne; Swansea University, Swansea University Medical School Atkinson, Mark; Swansea University, Swansea University Medical School Reinhold, Emma; Royal College of General Practitioners Choy, Ernest; Cardiff University, School of Medicine Lyons, Ronan; Swansea University, Swansea University Medical School Brophy, Sinead; Swansea University, Swansea University Medical School
Primary Subject Heading:	Public health
Secondary Subject Heading:	General practice / Family practice, Health informatics
Keywords:	Heritable Disorders of Connective Tissue, Ehlers-Danlos Syndromes, Joint Hypermobility Syndrome, Hypermobility Spectrum Disorder, Health Data Linkage, Prevalence

SCHOLARONE™
Manuscripts

1
2
3 **Diagnosed prevalence of Ehlers-Danlos syndrome and Hypermobility Spectrum**
4 **Disorder in Wales, UK: a national electronic cohort study and case-control**
5 **comparison**
6
7
8
9

10
11 Joanne C Demmler, Mark D Atkinson, Emma J Reinhold, Ernest Choy, Ronan A Lyons,
12 Sinead T Brophy
13

14
15
16
17
18 Joanne C Demmler, Lecturer, Health Data Research UK, Swansea University, Singleton
19 Park, Swansea SA2 8PP, UK. j.demmler@swansea.ac.uk.

20
21
22
23 Mark D Atkinson, Research Officer, Secure Anonymised Information Linkage (SAIL)
24 Databank, Swansea University, Singleton Park, Swansea SA2 8PP, UK.
25
26
27 m.atkinson@swansea.ac.uk.

28
29
30 Emma J Reinhold, RCGP Clinical Champion for the Ehlers-Danlos Syndromes, Clinical
31 Innovation and Research Centre, Royal College of General Practitioners, 30 Euston Square,
32 London, NW1 2FB. e.reinhold@doctors.org.uk.

33
34
35 Ernest Choy, Professor, Arthritis Research UK CREATE Centre, Section of Rheumatology,
36 Division of Infection and Immunity, Cardiff University, Cardiff CF14 4YS, UK.
37
38
39
40
41 ChoyEH@cardiff.ac.uk.

42
43
44 Ronan A Lyons, Professor, Health Data Research UK, Swansea University, Singleton Park,
45 Swansea SA2 8PP, UK. r.a.lyons@swansea.ac.uk.

46
47
48
49 Sinead T Brophy, Professor, Health Data Research UK, Swansea University, Singleton Park,
50 Swansea SA2 8PP, UK. s.brophy@swansea.ac.uk.

51
52
53
54
55
56 Correspondence to: JC Demmler j.demmler@swansea.ac.uk. Tel: 44 (0) 1792 295674
57
58
59
60

Abstract

Objectives: To describe the epidemiology of diagnosed Hypermobility Spectrum Disorder (HSD) and Ehlers-Danlos Syndromes (EDS) using linked electronic medical records. To examine whether these conditions remain rare and primarily affect the musculoskeletal system.

Design: Nationwide linked electronic cohort and nested case-control study

Setting: Routinely collected data from primary care and hospital admissions in Wales, UK.

Participants: People within the primary care or hospital data systems with a coded diagnosis of Ehlers-Danlos syndrome (EDS) or Joint Hypermobility Syndrome (JHS) between 01/07/1990 and 30/06/2017.

Main outcome measures: Combined prevalence of JHS and EDS in Wales. Additional diagnosis and prescription data in those diagnosed with EDS or JHS compared with matched controls.

Results: We found 6,021 individuals (male: 30%, female: 70%) with a diagnostic code of either EDS or JHS. This gives a diagnosed point prevalence of 194.2 per 100,000 in 2016/17 or roughly 10 cases in a practice of 5000 patients. There was a pronounced gender difference of 8.5 years (95% CI: 7.70 to 9.22) in the mean age at diagnosis. EDS or JHS was not only associated with high odds for other musculoskeletal diagnoses and drug prescriptions, but also with significantly higher odds of a diagnosis in other disease categories (e.g. mental health, nervous and digestive systems) and higher odds of a prescription in most disease categories (e.g. gastro-intestinal and cardiovascular drugs) within the 12 months before and after the first recorded diagnosis.

Conclusions: EDS and JHS (since March 2017 classified as EDS or HSD) have historically been considered rare diseases only affecting the musculoskeletal system and soft tissues. These data demonstrate that both of these assertions should be reconsidered.

1
2
3
4
5
6 **Key Words:** Heritable Disorders of Connective Tissue, Ehlers-Danlos Syndromes, Joint
7
8 Hypermobility Syndrome, Hypermobility Spectrum Disorder, Health Data Linkage,
9
10 Prevalence
11

12
13 **Word Count:** 3973
14
15

16 17 18 19 **Strengths and Limitations** 20

- 21
22 ● Large cohort and nested case-control studies based on whole population routinely
23 collected health data from primary and secondary care
24
- 25
26 ● We are unable to quantify how many people are suffering from hypermobile EDS
27 (hEDS) or HSD but remain undiagnosed, nor can we make any statement on the
28 reliability of the diagnoses
29
- 30
31 ● Although we only compared codes at Read chapter level all diagnoses and
32 prescriptions can be matched to conditions found in the EDS/JHS literature
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Introduction

The Ehlers-Danlos Syndromes (EDS) are a group of hereditary connective tissue disorders which mainly affect collagen. The nomenclature of these conditions has undergone a number of iterations which makes discussion of their prevalence complicated (see Textbox 1).

For many decades, studies have quoted a prevalence rate of 1 in 5000 for EDS, although the origin of this figure is unclear, seeming to appear first in a medical textbook^{1 2} as an unreferenced “reasonable estimate”. Thus, these syndromes have long been categorised as rare diseases, defined in the European Union as those affecting fewer than 50 in 100,000 people³. Kulas Søbørg et al.⁴ recently reported a prevalence of 20 per 100,000 for EDS in a nationwide Danish cohort based on secondary health care data up to 2012, but importantly, this data did not include patients who had received the considerably more common JHS diagnosis, now included in the latest revised classification. It is possible to extrapolate a combined population prevalence figure for JHS and EDS for Sweden⁵ of around 120 per 100,000 from a study focussing on comorbid mental health issues, but no investigators have thus far set out to investigate the combined diagnosed prevalence of JHS/EDS within a population.

Although common features of these conditions are arthralgia, soft tissue injury and joint instability⁶, over the last two decades it has become clear that their clinical features are not limited to musculoskeletal and cutaneous involvement, but are multisystemic⁷⁻⁹. In the special edition of the American Journal of Medical Genetics dedicated to EDS in March 2017, papers covered links to cardiovascular autonomic¹⁰ and gastrointestinal dysfunction¹¹ as well as psychiatric and neurodevelopmental disorders^{5 12}. Chronic disabling fatigue¹³ and pain syndromes¹⁴ were also recognised as common and multifactorial issues. Gynaecological^{15 16} and obstetric¹⁷ issues are also reported in this population. There is also an emerging link with the potentially life-threatening condition of Mast Cell Activation

1
2
3 Syndrome^{18 19}. There is some emerging evidence hinting that nutritional deficiencies^{20 21}
4 may play a key role, both seeming to be more prevalent in these patients and possibly
5 implicated in the development of some of the complications.
6
7
8

9
10 Early diagnosis is found to be crucial to patients²² to enable the provision of appropriate
11 treatment, as well as to prevent later onset complications⁷. Establishing the diagnosis of
12 EDS/HSD is often problematic for patients, which interferes with the early detection,
13 treatment and prevention of further escalations of recognised symptoms, disability and more
14 elaborate complications. A mean of 14 years elapses between the first clinical
15 manifestations and the actual diagnosis²³. For 25% of patients this delay lasts over 28 years
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
23. "A misdiagnosis was given to 56% of patients [resulting in] inappropriate treatment in 70%
of the patients... For 86% of the patients, the delay in diagnosis was considered responsible
for deleterious consequences." ^{23(p.137)}

It is possible that some of these difficulties arise from the widespread belief amongst
clinicians that EDS is rare. It is therefore of clinical importance to establish better estimates
of current prevalence. Conventional studies tend to be based in restricted clinical settings,
such as rheumatology clinics, and are therefore limited by the number of recruited patients
and biased by severity/type of patients referred. It has been shown that using linked health
data is an economic and effective alternative to performing *de novo* longitudinal studies,
including rare conditions^{24 25}. We used routinely held data from primary and secondary care
sources to examine the epidemiology of people with a diagnostic code for EDS/JHS in
Wales. We then conducted a nested case- control study to study the number of diagnoses
across all body/disease systems and prescription usage in order to test the widespread
belief that these conditions are primarily musculoskeletal in nature, rather than multi-system
disorders.

Methods

Study design: Nationwide electronic cohort study

Anonymised record linkage and hosting is carried out in the Secure Anonymised Information Linkage (SAIL) databank²⁶ on routinely collected data held in health and social care datasets. All data within the SAIL gateway are treated in accordance with the Data Protection Act 2018 and complies with GDPR.

We used data from a variety of datasets between 01/07/1990 and 30/06/2017 to create the anonymised e-cohort and case control studies. The Primary Care data covers about 80% of all coded information held by General Practitioners (GPs) in Wales. The Welsh Demographics Service (WDS) contains key statistics, such as gender, week of birth, date of death and practice migration status for everyone in Wales registered with a GP. The Patient Episode Database for Wales (PEDW) contains all inpatient hospital admissions to a Welsh hospital. WDS and PEDW data are available for the whole of Wales. The SAIL databank enables the anonymised matching of individuals across these different datasets using a person level anonymised linkage field (ALF)²⁶.

Cohort preparation

We identified Welsh residents with a Read Version 2²⁷ diagnostic code of EDS or JHS in primary care data or ICD-10 diagnostic codes²⁸ in secondary care data (hospital admissions) between 01/07/1990 (or the start of the dataset if later) and 30/06/2017. This date marks the end of maximum data coverage across all datasets. The EDS sub-classification in Read Version 2 contains some, but not all, of the subtypes which were in use prior to 1997 and as a result, the reliability of any subtype data must be highly questionable (see Table 1). Due to the lack of available correct sub-codes for EDS subtypes, the fact that the overwhelming majority of patients simply had the header code (86% of those coded as EDS, with a further 12% coded as hEDS), and that other EDS types are genuinely rare, all codes for EDS were combined. ICD-10 codes do not distinguish between any subtypes of EDS (see Table 1). Only ALF's with good matching status were included in the

1
2
3 study, i.e. direct match on either NHS number or on surname, first name, postcode, date of
4 birth and gender; or fuzzy matching with a probability of $\geq 90\%$.
5
6

7
8 We created one dataset for diagnoses in the GP data and another for diagnoses in the
9 hospital data. Both datasets were linked to the week of birth, gender and date of death
10 information in WDS on their ALF and then combined to create a cohort of people with
11 EDS/JHS in either GP or hospital data, identifying any duplications and keeping the earliest
12 diagnosis date for any individual appearing in both datasets.
13
14
15
16
17

18 19 **Analysis**

20
21 Data linkage and data preparation within the SAIL databank were conducted using IBM DB2
22 10.5 SQL. Data were then imported into R (Version 3.4.1)²⁹, which was used for all
23 statistical analyses. The mean age at first diagnosis between male and female subjects was
24 compared and confidence intervals of the difference calculated.
25
26
27
28
29

30
31 The denominator of the diagnosed prevalence and incidence of EDS and JHS in secondary
32 care was calculated based on the total number of individuals with recorded gender,
33 registered and living in Wales between 01/07/1990 and 30/06/2017 for each full year of the
34 study respectively. The prevalence and incidence in primary care denominator was further
35 adjusted to include only people living in Wales and whose GP practice was contributing data
36 to SAIL. The prevalence and incidence in primary and secondary care was then added
37 together to create an overall estimate of the prevalence and incidence in Wales.
38
39
40
41
42
43
44
45

46 47 **Case-Control Comparison**

48
49 A nested case control method was used. Each case was matched to 4 controls with the
50 same gender and similar age profiles (within 45 days of the week of birth). We implemented
51 strict criteria for selection to the case-control cohort. Both cases and controls had to (a) have
52 uninterrupted GP registrations for 1 year before and 1 year after the date of the relevant
53 diagnosis (or died during follow-up); (b) be registered with a GP submitting data to SAIL
54 either at the matching date or afterwards; (c) have been registered with a GP that
55
56
57
58
59
60

1
2
3 consistently recorded data across their patient profile. The latter avoids diagnoses that were
4 retrospectively entered for a time period when the GP practice did not fully implement the
5 use of electronic records (less than 10% of the data they recorded during 2009). Although
6 this reduced the number of cases and controls we were able to analyse, it avoids data
7 quality bias, especially during the early years of this study, when GPs were converting to the
8 use of computer systems and databases. Controls with any type of diagnosed hereditary
9 connective tissue disorder were excluded. Preliminary analysis of the combined cohort
10 indicated that adjustment for deprivation was not necessary (i.e. equal distribution of people
11 across deprivation quintiles). We then calculated odds ratios between cases and controls
12 using Read chapters (excluding the Read codes for EDS and JHS). This method counts the
13 number of people with a code in each category; multiple codes for the same person in the
14 same category are therefore not included. All results that affected at least 5 cases or 20
15 controls were visualised using forest plots.

31 **Ethical approval**

32
33 The study design uses anonymised data and therefore the need for ethical approval and
34 participant consent was waived by the approving Institutional Review Board, the UK National
35 Health Service Research Ethics Committee. The SAIL independent Information Governance
36 Review Panel (IGRP) approved the study.

43 **Patient and Public Involvement**

44
45 Two of the authors of this paper have been diagnosed with symptomatic joint hypermobility
46 disorders. This study used routinely collected data, we were not able to involve members of
47 the public but will be disseminating our findings widely, including directly to patients via
48 social media and through our links with patient organisations.

55 **Results**

58 **EDS/JHS in Primary Care data**

1
2
3 5,355 individuals with a diagnosis of either EDS or JHS with valid birth and gender
4 information were identified. Of these, 4,654 (87%) had a diagnosis of JHS and 701 (13%) of
5 EDS. The Read code for the EDS subtype was only used for 136 (19%) individuals with 114
6 (16%) identified as EDS-Hypermobility Type and 22 (3%) as other EDS subtypes. 3,759
7 (70%) of those diagnosed with EDS/JHS were female (see Figure 1).
8
9
10
11
12

13 **EDS/JHS in Hospital Data**

14
15
16
17 A total of 1,298 individuals were found in the hospital data of whom 970 (75%) were female:
18 745 (57%) had a diagnosis of JHS and 553 (43%) EDS (see Figure 1).
19
20
21

22 **Demographics of combined EDS/JHS cohort**

23
24
25 5,355 (89%) of the cases could be found in the primary care data with the remainder in the
26 hospital cohort. Combining the results from primary and secondary care led to a cohort of
27 6,021 distinct individuals. 5,064 (84%) were coded with JHS and 957 (16%) with EDS. 4,244
28 (70%) of patients were female. The age at first diagnosis peaked in the age group 5-9 years
29 for males and 15-19 years for females (see Figure 2). There was a significant difference of
30 8.5 years in the mean age of diagnosis between males and females (95% CI: 7.70 to 9.22):
31 9.6 years in EDS (95% CI: 6.85 to 12.31) and 8.3 years in JHS (95% CI: 7.58 to 9.11). 72%
32 of males were diagnosed during childhood (age < 18 years) in contrast to only 41% of
33 females.
34
35
36
37
38
39
40
41
42
43

44
45 2016/17 is the latest year for which we have complete data and could therefore derive
46 prevalence. During this year, 2,668,902 people were registered with a GP in Wales
47 submitting data to SAIL, of whom 4,598 had a diagnostic code of EDS/JHS which first
48 appeared in the primary care data (172 in 100,000). A further 711 people out of the
49 3,239,153 registered with any GP in Wales during 2016/17 had an EDS/JHS diagnosis
50 which first appears in secondary care data (22 in 100,000). There is an increasing rate of
51 coded diagnoses throughout the period. Assuming that the GP data is representative of the
52 whole of Wales this leads to a combined point prevalence of 194 in 100,000 at the end of the
53
54
55
56
57
58
59
60

1
2
3 study period. This corresponds to about 10 cases in a practice of 5000 patients (see Figure
4 3). The incidence of EDS/JHS over this time period is shown in Supplement Figure 1.
5
6
7

8 **Factors associated with JHS/EDS**

9
10 2,597 cases had good GP data coverage at the age of diagnosis and could be matched by
11 age and gender with controls (see Figure 1). 1,340 cases (male: 561; female: 779) were first
12 diagnosed before the age of 18 years and 1,254 cases (male: 229; female: 1,025) above this
13 age. The people in the nested case-control cohort were slightly older than the overall cohort
14 (data not shown here).
15
16
17
18
19
20
21

22 Looking at the time frame of 1 year either side of the first coded diagnosis of EDS/JHS
23 amongst young people (age < 18 years) there were significantly more additional diagnoses
24 in 16 out of 20 Read code disease categories compared with their controls (see Figure 4a).
25 The top three Read diagnosis chapters with increased odds for the EDS/JHS cohort were for
26 musculoskeletal conditions (OR 9.36, 95% CI: 7.98 to 11.00), congenital anomalies (OR
27 5.89; 95% CI: 3.98 to 8.80) and mental disorders (OR 4.16; 95% CI: 3.29 to 5.27).
28
29
30
31
32
33
34

35 People that were diagnosed as adults (age \geq 18 years) had also significantly more
36 diagnoses in 16 out of 20 Read code categories than their controls (see Figure 4b). The top
37 three Read diagnosis chapters for adults with higher odds in the EDS/JHS cohort were
38 musculoskeletal disorders (OR 7.95; 95% CI: 6.95 to 9.12), congenital anomalies (OR 5.18;
39 95% CI: 2.78 to 9.78) and symptoms, signs and ill-defined conditions (OR 2.9; 95% CI: 2.5
40 to 3.37). Circulatory system disease (OR 2.29; 95% CI: 1.83 to 2.86) and mental disorders
41 remained significant (OR 1.87; 95% CI: 1.57 to 2.22), but not to the same extent as they
42 were for young people.
43
44
45
46
47
48
49
50
51

52 Young people showed significantly higher odds for prescriptions in 14 out of 17 Read code
53 categories than their controls (see Figure 5a). The top three prescriptions Read chapters
54 with increased odds for the EDS/JHS cohort were for (i) musculoskeletal drugs (OR 3.65;
55
56
57
58
59
60

1
2
3 95% CI: 3.18 to 4.18), (ii) gastro-intestinal drugs (OR 3.02; 95% CI: 2.54 to 3.58) and (iii)
4
5 haematology/dietetic drugs (OR 2.54; 95% CI: 2.06 to 3.11).
6
7

8 Adults had significantly higher odds of prescriptions for 15 out of 17 Read code categories
9
10 (see Figure 5b). The top three prescriptions with higher odds for EDS/JHS people were for
11
12 (i) musculoskeletal drugs (OR 5.17; 95% CI: 4.53 to 5.9), (ii) central nervous system drugs
13
14 (OR 3.9; 95% CI: 3.41 to 4.46) and (iii) chemotherapy/immunosuppressant drugs (OR 3.03;
15
16 95% CI: 1.89 to 4.8). Gastro-intestinal drugs (OR 2.85; 95% CI: 2.5 to 3.24) and
17
18 haematology/dietetic drugs (OR 2.21; 95% CI: 1.9 to 2.57) remain significant, but at slightly
19
20 lower levels than in the young EDS/JHS population.
21
22

23 Discussion

24
25
26
27 This work examined the epidemiology of EDS and JHS and found a combined diagnosed
28
29 prevalence of 194.2 per 100,000 (0.19%), or 1 in 500 people in Wales; hEDS or HSD within
30
31 the 2017 classification. We found a steadily increasing rate of diagnosis over the past 27
32
33 years (see Supplement Figure 1), as well as higher rates of diagnoses for other conditions
34
35 and prescriptions within 12 months (pre and post) of the recorded first diagnosis in most
36
37 categories. This suggests that hEDS/HSD, when considered together, do not meet the
38
39 definition of rare conditions²³, and have widespread effects across multiple body systems.
40
41 It is well-known that EDS is poorly recognised in children^{30 31} and initial symptoms and EDS-
42
43 associated diagnoses can appear to be simply a 'normal' pattern of childhood illness when
44
45 taken as an isolated event. Furthermore, children with hEDS often present with symptoms
46
47 that can lead to a misdiagnosis of mental illness or consideration of child abuse^{12 32}.
48
49 Suspicion of abuse has been shown to be extremely damaging to the mental health of the
50
51 parent(s) and can lead to an avoidance of accessing health care or other public services,
52
53 such as schools³³. The prolonged and sometimes traumatic diagnosis and/or misdiagnosis
54
55 process in EDS can lead to further disengagement with services³⁴. The lack of a timely
56
57 diagnosis has great implications for disease management and progression and impedes the
58
59
60

1
2
3 appropriate consideration of surgical interventions ^{7 35-38} as well as pregnancy and birth
4 planning ¹⁷. It is perhaps only in stepping back to look at the pattern of effects across
5 multiple body systems that practitioners might begin to consider a connective tissue
6 disorder.
7
8
9
10

11 **Strengths and Limitations**

12
13
14
15 The strength of this study is that we were able to combine diagnostic codes from several
16 primary and secondary health care providers to create a large cohort of individuals with
17 EDS/JHS. We have 27 years of data with at least 11 years of very good data coverage in the
18 key datasets, which further improves with each data update of the SAIL databank, however
19 data coverage for the first couple of years is less comprehensive.
20
21
22
23
24

25
26 The majority of subjects were identified via their primary care data, which is a strength and a
27 weakness. As 89% of cases were identified through primary care data studies not using
28 primary care data may underestimate the prevalence of hEDS/HSD. We are unable to
29 quantify how many people are suffering from hEDS or HSD but remain undiagnosed.
30
31 However, we cannot comment on the reliability of the diagnoses in the primary care dataset.
32
33 It is also likely that the majority of cases were not actually diagnosed in primary care, but
34 their entries were created through secondary care contacts, such as outpatient appointments
35 or musculoskeletal assessment clinics, but coded data are lacking from these sources.
36
37
38
39
40
41
42
43

44 Although a snapshot of Read chapters codes that are more prevalent in our JHS/EDS cohort
45 does not allow us to look at specific diagnoses and prescriptions, they can all be matched to
46 conditions associated with EDS/JHS in the literature, for instance pain, fatigue,
47 cardiovascular, gastrointestinal and gynaecological disorders, dysautonomia, mast cell
48 activation as well as urinary tract infections ⁷. It needs to be stressed that these results
49 exclude codes for EDS/JHS and that these are not part of the results for congenital
50 anomalies or musculoskeletal conditions. We hope in future work to examine in greater
51 detail these findings of significant differences between people with hEDS/HSD and others in
52
53
54
55
56
57
58
59
60

1
2
3 order that we can better understand the nature of this condition, as well as potentially
4 improving diagnostic recognition. For instance, immunosuppressant drugs are in the same
5 Read chapter as chemotherapy drugs. Higher use of these prescriptions in the hEDS/HSD
6 cohort could plausibly be linked to the known increased comorbid existence of disorders
7 such as inflammatory bowel disease, inflammatory arthropathies, systemic lupus
8 erythematosus and other autoimmune conditions ³⁹, and is less likely to be due to a higher
9 rate of use of chemotherapeutic agents.
10
11

12 We conclude that EDS/HSD are not rare conditions and are associated with significantly
13 increased odds of additional diagnoses and use of medications across many body systems.
14 There is a large gender difference in the age of diagnosis, with many women not diagnosed
15 until adulthood. Early diagnosis, however, is crucial to patients, the administration of
16 preventive therapies, the investigation of comorbid conditions and the overall management
17 process. Further research is needed to understand patient pathways, comorbidities and
18 progression of associated symptoms and diseases. Health services should be aware of
19 these findings for the provision of training, diagnostic and treatment services for the many
20 tens of thousands of patients living with these life-changing conditions throughout the United
21 Kingdom and beyond.
22
23

24 **Author contributions**

25 JD conceived the project. SB and MA contributed to the study design and analysis plan. RAL
26 validated clinical codes in primary care. EC validated clinical codes in secondary care. JD
27 undertook the analysis. JD and ER carried out the literature reviews and drafted the
28 manuscript. All authors reviewed the manuscript and approved the final version for
29 submission.
30
31

32 **Funding**

33 This work was supported by The Farr Institute. The Farr Institute was supported by a 10-funder
34 consortium: Arthritis Research UK, the British Heart Foundation, Cancer Research UK, the
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 Economic and Social Research Council, the Engineering and Physical Sciences Research
4 Council, the Medical Research Council, the National Institute of Health Research, the National
5 Institute for Social Care and Health Research (Welsh Assembly Government), the Chief
6 Scientist Office (Scottish Government Health Directorates), the Wellcome Trust, (MRC Grant
7 No: MR/K006525/1).

8
9
10
11
12
13
14 This work was also supported by Health Data Research UK which receives its funding from
15 HDR UK Ltd (NIWA1) funded by the UK Medical Research Council, Engineering and Physical
16 Sciences Research Council, Economic and Social Research Council, Department of Health
17 and Social Care (England), Chief Scientist Office of the Scottish Government Health and
18 Social Care Directorates, Health and Social Care Research and Development Division (Welsh
19 Government), Public Health Agency (Northern Ireland), British Heart Foundation (BHF) and
20 the Wellcome Trust.

21
22
23
24
25
26
27
28
29
30 The above funders played no role in the study design, in the collection, analysis, or
31 interpretation of data; in the writing of the report; or in the decision to submit the article for
32 publication. The researchers are independent from the funders and all authors, external and
33 internal, had full access to all of the data in the study and take responsibility for the integrity
34 of the data and the accuracy of the data analysis.

35
36
37
38
39
40
41
42 Competing interests: All authors have completed the ICMJE uniform disclosure form at
43 www.icmje.org/coi_disclosure.pdf and declare: no support from any organisation for the
44 submitted work; no financial relationships with any organisations that might have an interest
45 in the submitted work in the previous three years; no other relationships or activities that
46 could appear to have influenced the submitted work.

47
48
49
50
51
52
53
54
55 Exclusive licence: The Corresponding Author has the right to grant on behalf of all authors
56 and does grant on behalf of all authors, a worldwide licence
57 (<http://www.bmj.com/sites/default/files/BMJ%20Author%20Licence%20March%202013.doc>)
58
59
60

1
2
3 to the Publishers and its licensees in perpetuity, in all forms, formats and media (whether
4 known now or created in the future), to i) publish, reproduce, distribute, display and store the
5 Contribution, ii) translate the Contribution into other languages, create adaptations, reprints,
6 include within collections and create summaries, extracts and/or, abstracts of the
7 Contribution and convert or allow conversion into any format including without limitation
8 audio, iii) create any other derivative work(s) based in whole or part on the on the
9 Contribution, iv) to exploit all subsidiary rights to exploit all subsidiary rights that currently
10 exist or as may exist in the future in the Contribution, v) the inclusion of electronic links from
11 the Contribution to third party material wherever it may be located; and, vi) licence any third
12 party to do any or all of the above. All research articles will be made available on an open
13 access basis (with authors being asked to pay an open access fee—see
14 [http://www.bmj.com/about-bmj/resources-authors/forms-policies-and-checklists/copyright-](http://www.bmj.com/about-bmj/resources-authors/forms-policies-and-checklists/copyright-open-access-and-permission-reuse)
15 [open-access-and-permission-reuse](http://www.bmj.com/about-bmj/resources-authors/forms-policies-and-checklists/copyright-open-access-and-permission-reuse)). The terms of such open access shall be governed by a
16 Creative Commons licence—details as to which Creative Commons licence will apply to the
17 research article are set out in our worldwide licence referred to above.

18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37 Transparency declaration: The lead author affirms that this manuscript is an honest,
38 accurate, and transparent account of the study being reported; that no important aspects of
39 the study have been omitted; and that any discrepancies from the study as planned (and, if
40 relevant, registered) have been explained.

41
42
43
44
45
46
47 Dissemination statement: We are planning to disseminate our results to patient groups using
48 social media.

49
50
51
52
53 Data sharing statement: The data used in this study are available in the SAIL databank at
54 Swansea University, Swansea, UK. All proposals to use SAIL data are subject to review by
55 an independent Information Governance Review Panel (IGRP). Before any data can be
56 accessed, approval must be given by the IGRP.

The IGRP gives careful consideration to each project to ensure proper and appropriate use of SAIL data. When access has been granted, it is gained through a privacy-protecting safe haven and remote access system referred to as the SAIL Gateway. SAIL has established an application process to be followed by anyone who would like to access data via SAIL <https://www.saildatabank.com/application-process>.

Additional resources: RCGP Clinical Toolkit on the Ehlers-Danlos Syndromes

www.rcgp.org.uk/eds; RCGP Podcast "Introduction to Ehlers-Danlos Syndromes"

<https://audioboom.com/posts/6896541-introduction-to-ehlers-danlos-syndromes>

References

1. Cecil RLF, Goldman L, Bennett JC. Cecil Textbook of Medicine: W.B. Saunders 2000.
2. Mulvey MR, Macfarlane GJ, Beasley M, et al. Modest Association of Joint Hypermobility With Disabling and Limiting Musculoskeletal Pain: Results From a Large-Scale General Population-Based Survey. *Arthritis Care & Research* 2013;65(8):1325-33. doi: 10.1002/acr.21979
3. Commission of the European Communities Communication from the Commission to the European Parliament, the Council, the European Economic and Social Committee and the Committee of the regions on Rare Diseases: Europe's challenges. Brussels: Commission of the European Communities, 2008.
4. Søbørg M-LK, Leganger J, Mortensen LQ, et al. Establishment and baseline characteristics of a nationwide Danish cohort of patients with Ehlers–Danlos syndrome. *Rheumatology (Oxford)* 2017;56(5):763-67. doi: 10.1093/rheumatology/kew478
5. Cederlöf M, Larsson H, Lichtenstein P, et al. Nationwide population-based cohort study of psychiatric disorders in individuals with Ehlers-Danlos syndrome or hypermobility syndrome and their siblings. *Bmc Psychiatry* 2016;16 doi: 10.1186/s12888-016-0922-6
6. Hakim AJ, Grahame R. A simple questionnaire to detect hypermobility: An adjunct to the assessment of patients with diffuse musculoskeletal pain. *International Journal of Clinical Practice* 2003;57(3):163-66.
7. Tinkle B, Castori M, Berglund B, et al. Hypermobility Ehlers-Danlos Syndrome (a.k.a. Ehlers-Danlos Syndrome Type III and Ehlers-Danlos Syndrome Hypermobility Type): Clinical Description and Natural History. *American Journal of Medical Genetics Part C-Seminars in Medical Genetics* 2017;175(1):48-69. doi: 10.1002/ajmg.c.31538
8. Gazit Y, Jacob G, Grahame R. Ehlers-Danlos Syndrome-Hypermobility Type: A Much Neglected Multisystemic Disorder. *Rambam Maimonides Medical Journal* 2016;7(4) doi: 10.5041/rmmj.10261
9. De Paepe A, Malfait F. The Ehlers-Danlos syndrome, a disorder with many faces. *Clinical Genetics* 2012;82(1):1-11. doi: 10.1111/j.1399-0004.2012.01858.x
10. Hakim A, O'Callaghan C, De Wandele I, et al. Cardiovascular Autonomic Dysfunction in Ehlers-Danlos Syndrome-Hypermobility Type. *American Journal of Medical Genetics*

- 1
2
3 *Part C-Seminars in Medical Genetics* 2017;175(1):168-74. doi:
4 10.1002/ajmg.c.31543
- 5 11. Fikree A, Chelimsy G, Collins H, et al. Gastrointestinal Involvement in the Ehlers-
6 Danlos Syndromes. *American Journal of Medical Genetics Part C-Seminars in*
7 *Medical Genetics* 2017;175(1):181-87. doi: 10.1002/ajmg.c.31546
- 8 12. Bulbena A, Baeza-Velasco C, Bulbena-Cabre A, et al. Psychiatric and Psychological
9 Aspects in the Ehlers-Danlos Syndromes. *American Journal of Medical Genetics Part*
10 *C-Seminars in Medical Genetics* 2017;175(1):237-45. doi: 10.1002/ajmg.c.31544
- 11 13. Hakim A, De Wandele I, O'Callaghan C, et al. Chronic Fatigue in Ehlers-Danlos
12 Syndrome-Hypermobility Type. *American Journal of Medical Genetics Part C-*
13 *Seminars in Medical Genetics* 2017;175(1):175-80. doi: 10.1002/ajmg.c.31542
- 14 14. Chopra P, Tinkle B, Hamonet C, et al. Pain Management in the Ehlers-Danlos
15 Syndromes. *American Journal of Medical Genetics Part C-Seminars in Medical*
16 *Genetics* 2017;175(1):212-19. doi: 10.1002/ajmg.c.31554
- 17 15. Veit-Rubin N, Cartwright R, Singh AU, et al. Association between joint hypermobility and
18 pelvic organ prolapse in women: a systematic review and meta-analysis.
19 *International Urogynecology Journal* 2016;27(10):1469-78. doi: 10.1007/s00192-015-
20 2896-1
- 21 16. Hugon-Rodin J, Lebegue G, Becourt S, et al. Gynecologic symptoms and the influence
22 on reproductive life in 386 women with hypermobility type ehlers-danlos syndrome: a
23 cohort study. *Orphanet Journal of Rare Diseases* 2016;11 doi: 10.1186/s13023-016-
24 0511-2
- 25 17. Pezaro S, Pearce G, Reinhold E. Hypermobility Ehlers-Danlos Syndrome during
26 pregnancy, birth and beyond. *British Journal of Midwifery* 2018;26(4):217-23. doi:
27 10.12968/bjom.2018.26.4.217
- 28 18. Seneviratne SL, Maitland A, Afrin L. Mast Cell Disorders in Ehlers-Danlos Syndrome.
29 *American Journal of Medical Genetics Part C-Seminars in Medical Genetics*
30 2017;175(1):226-36. doi: 10.1002/ajmg.c.31555
- 31 19. Cheung I, Vadas P. A New Disease Cluster: Mast Cell Activation Syndrome, Postural
32 Orthostatic Tachycardia Syndrome, and Ehlers-Danlos Syndrome. *Journal of Allergy*
33 *and Clinical Immunology* 2015;135(2):AB65-AB65.
- 34 20. Mantle D, Wilkins RM, Preedy V. A novel therapeutic strategy for Ehlers-Dantos
35 syndrome based on nutritional supplements. *Medical Hypotheses* 2005;64(2):279-83.
36 doi: 10.1016/j.mehy.2004.07.023
- 37 21. Castori M, Morlino S, Pascolini G, et al. Gastrointestinal and Nutritional Issues in Joint
38 Hypermobility Syndrome/Ehlers-Danlos Syndrome, Hypermobility Type. *American*
39 *Journal of Medical Genetics Part C-Seminars in Medical Genetics* 2015;169(1):54-
40 75. doi: 10.1002/ajmg.c.31431
- 41 22. Terry RH, Palmer ST, Rimes KA, et al. Living with joint hypermobility syndrome: patient
42 experiences of diagnosis, referral and self-care. *Family Practice* 2015;32(3):354-58.
43 doi: 10.1093/fampra/cmz026
- 44 23. EURORDIS AKFF. The Voice of 12,000 Patients. Experiences and Expectations of Rare
45 Disease Patients on Diagnosis and Care in Europe: Eurordis 2009.
- 46 24. Holman CDJ, Bass AJ, Rosman DL, et al. A decade of data linkage in Western Australia:
47 strategic design, applications and benefits of the WA data linkage system. *Australian*
48 *Health Review* 2008;32(4):766-77.
- 49 25. Cooksey R, Husain MJ, Brophy S, et al. The Cost of Ankylosing Spondylitis in the UK
50 Using Linked Routine and Patient-Reported Survey Data. *Plos One* 2015;10(7) doi:
51 10.1371/journal.pone.0126105
- 52 26. Lyons RA, Jones KH, John G, et al. The SAIL databank: linking multiple health and
53 social care datasets. *Bmc Medical Informatics and Decision Making* 2009;9 doi:
54 10.1186/1472-6947-9-3
- 55 27. Chisholm J. The READ Clinical Classification. *Brit Med J* 1990;300(6732):1092-92.
- 56 28. World Health Organization. ICD-10: International statistical classification of diseases and
57 related health problems: World Health Organization 2016.
- 58
59
60

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
29. R: A Language and Environment for Statistical Computing [program]. Vienna, Austria: R Foundation for Statistical Computing, 2017.
30. Adib N, Davies K, Grahame R, et al. Joint hypermobility syndrome in childhood. A not so benign multisystem disorder? *Rheumatology* 2005;44(6):744-50. doi: 10.1093/rheumatology/keh557
31. Grahame R, Hakim AJ. Joint Hypermobility Syndrome is highly prevalent in general rheumatology clinics, its occurrence and clinical presentation being gender, age and race-related. *Annals of the Rheumatic Diseases* 2006;65:263-63.
32. Castori M. Ehlers-Danlos Syndrome(s) Mimicking Child Abuse: Is There an Impact on Clinical Practice? (vol 169, pg 289, 2015). *American Journal of Medical Genetics Part A* 2016;170(7):1947-47. doi: 10.1002/ajmg.a.37733
33. Association for Improvements in Maternity Services (AIMS). The Child Protection System in England: Written evidence submitted by the Association for Improvements in the Maternity Services (AIMS) 2011 [Available from: <http://www.publications.parliament.uk/pa/cm201012/cmselect/cmeduc/writev/1514/cp29.htm> accessed 14/02/2019.
34. Berglund B, Anne-Cathrine M, Randers I. Dignity not fully upheld when seeking health care: Experiences expressed by individuals suffering from Ehlers–Danlos syndrome. *Disability and Rehabilitation* 2010;32(1):1-7. doi: 10.3109/09638280903178407
35. Scheper MC, Nicholson LL, Adams RD, et al. The natural history of children with joint hypermobility syndrome and Ehlers-Danlos hypermobility type: a longitudinal cohort study. *Rheumatology* 2017;56(12):2073-83. doi: 10.1093/rheumatology/kex148
36. Engelbert RHH, Juul-Kristensen B, Pacey V, et al. The Evidence-Based Rationale for Physical Therapy Treatment of Children, Adolescents, and Adults Diagnosed With Joint Hypermobility Syndrome/Hypermobility Ehlers Danlos Syndrome. *American Journal of Medical Genetics Part C-Seminars in Medical Genetics* 2017;175(1):158-67. doi: 10.1002/ajmg.c.31545
37. Ericson WB, Wolman R. Orthopaedic Management of the Ehlers-Danlos Syndromes. *American Journal of Medical Genetics Part C-Seminars in Medical Genetics* 2017;175(1):188-94. doi: 10.1002/ajmg.c.31551
38. Soborg MLK, Leganger J, Rosenberg J, et al. Increased Need for Gastrointestinal Surgery and Increased Risk of Surgery-Related Complications in Patients with Ehlers-Danlos Syndrome: A Systematic Review. *Digestive Surgery* 2017;34(2):161-70. doi: 10.1159/000449106
39. Rodgers KR, Gui J, Dinulos MBP, et al. Ehlers-Danlos syndrome hypermobility type is associated with rheumatic diseases. *Scientific Reports* 2017;7 doi: 10.1038/srep39636
40. Sobey G. Ehlers-Danlos syndrome: how to diagnose and when to perform genetic tests. *Archives of Disease in Childhood* 2015;100(1):57-61. doi: 10.1136/archdischild-2013-304822
41. Grahame R, Bird HA, Child A, et al. The revised (Brighton 1998) criteria for the diagnosis of benign joint hypermobility syndrome (BJHS). *Journal of Rheumatology* 2000;27(7):1777-79.
42. Beighton P, De Paepe A, Steinmann B, et al. Ehlers-Danlos syndromes: Revised nosology, Villefranche, 1997. *American Journal of Medical Genetics* 1998;77(1):31-37. doi: 10.1002/(sici)1096-8628(19980428)77:1<31::aid-ajmg8>3.0.co;2-o
43. Grahame R. Joint hypermobility and genetic collagen disorders: are they related? *Archives of Disease in Childhood* 1999;80(2):188-91.
44. Malfait F, Francomano C, Byers P, et al. The 2017 International Classification of the Ehlers-Danlos Syndromes. *American Journal of Medical Genetics Part C-Seminars in Medical Genetics* 2017;175(1):8-26. doi: 10.1002/ajmg.c.31552
45. Castori M, Dordoni C, Morlino S, et al. Spectrum of Mucocutaneous Manifestations in 277 Patients with Joint Hypermobility Syndrome/Ehlers-Danlos Syndrome, Hypermobility Type. *American Journal of Medical Genetics Part C-Seminars in Medical Genetics* 2015;169(1):43-53. doi: 10.1002/ajmg.c.31425

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1: Clinical coding for Ehlers-Danlos Syndromes and Joint Hypermobility Syndrome.

Read code descriptions (based on pre-1997 nomenclature)	EDS type according to the Villefranche Criteria	EDS Type according to the March 2017 Criteria	Read code version 2	ICD10 code
Ehlers-Danlos syndrome			PGy2.	Q79.6
Ehlers-Danlos syndrome type I	Classical type	Classical EDS	PGy20	
Ehlers-Danlos syndrome type II			PGy21	
Ehlers-Danlos syndrome type III	Hypermobility type	Hypermobility EDS or Hypermobility Spectrum Disorder	PGy22	
Ehlers-Danlos syndrome type IV	Vascular type	Vascular EDS	PGy23	
Ehlers-Danlos syndrome type V	X-linked type	No longer classified as EDS	PGy24	
Ehlers-Danlos syndrome type VI	Kyphoscoliotic type	Kyphoscoliotic EDS	PGy25	
Ehlers-Danlos syndrome type VII	Arthrochalasia type Dermatosparaxis type	Arthrochalasia EDS Dermatosparaxis EDS	PGy26	
Ehlers-Danlos syndrome type VIII	Periodontitis type	Periodontal EDS	PGy27	
Hypermobility Syndrome (JHS according to the Brighton Criteria)	(Hypermobility type)	Hypermobility EDS or Hypermobility Spectrum Disorder	N235.	728.5

Textbox 1: An overview of the Ehlers-Danlos Nomenclature

Ehlers Danlos Syndrome Nomenclature

- Joint hypermobility *per se* is reasonably common and thought to be present in around 10% of the general UK population ⁴⁰.
- The Brighton criteria were used to diagnose Joint Hypermobility Syndrome from 1998 ⁴¹,
- The Villefranche criteria were applied to confirm EDS-Hypermobility Type from 1997 ⁴².
- Prior to the Villefranche criteria, the diagnosis EDS III was used to denote the hypermobile subtype of EDS.
- It was recognised over a number of years that JHS and EDS-HT were not distinct from one another ⁴³.
- In March 2017 the International Consortium on the Ehlers Danlos Syndromes published a revised classification ⁴⁴ naming two syndromes:
 - Hypermobile EDS (hEDS) which has narrowly defined criteria
 - Hypermobility Spectrum Disorder (HSD) for those with some but not all of the features of hEDS
- Patients who have a diagnosis of EDS-HT or JHS will fall into one of these two new categories.
- Castori et al showed that patients may move from the HSD category into hEDS over time: they also emphasised that the approach to management and the prognosis in terms of disability are the same ⁴⁵. One may therefore conclude that health needs across these groups are similar.

Figures

Figure 1: Flow diagram of EDS/JHS cohort and case-control cohort creation. Figure 2: Age at first coded diagnosis of EDS/JHS by age group and gender.

Figure 3: Prevalence of coded diagnosis of JHS/EDS in Primary Care, hospital inpatient and combined over time.

Figure 4: Odds ratios of Read chapter diagnoses for (a) young people (<18 years of age) and (b) adults (>= 18 years of age) within 12 months before and after EDS/JHS diagnosis.

Presented are all results that affect at least 5 cases or 20 controls (perinatal conditions,

1
2
3 chapter Q, are not shown as neither young people nor adults had the required minimum
4
5 number of cases/controls).
6
7


8 Figure 5: Odds ratios of Read chapter prescriptions for young people (<18 years of age) and
9
10 adults (≥ 18 years of age) within 12 months before and after EDS/JHS diagnosis.
11

12 Presented are all results that affect at least 5 cases or 20 controls (incontinence and stoma
13
14 appliances, chapters q and s, are not shown as neither young people nor adults had the
15
16 required minimum number of cases/results).
17
18

19 **Supplement Figures**


20
21
22 Supplement Figure 1: Incidence of diagnosis of JHS/EDS in GP, hospital inpatient and
23
24 combined data over time.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



Flow diagram of EDS/JHS cohort and case-control cohort creation

209x297mm (300 x 300 DPI)




Age at first coded diagnosis of EDS/JHS by age group and gender

177x152mm (300 x 300 DPI)


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Prevalence of coded diagnosis of JHS/EDS in Primary Care, hospital inpatient and combined over time

177x152mm (300 x 300 DPI)




Odds ratios of Read chapter diagnoses for (a) young people (<18 years of age) and (b) adults (>= 18 years of age) within 12 months before and after EDS/JHS diagnosis. Presented are all results that affect at least 5 cases or 20 controls (perinatal conditions, chapter Q, are not shown as neither young people nor adults had the required minimum number of cases/controls)

177x127mm (300 x 300 DPI)



Odds ratios of Read chapter prescriptions for young people (<18 years of age) and adults (>= 18 years of age) within 12 months before and after EDS/JHS diagnosis. Presented are all results that affect at least 5 cases or 20 controls (incontinence and stoma appliances, chapters q and s, are not shown as neither young people nor adults had the required minimum number of cases/results)

177x127mm (300 x 300 DPI)



177x152mm (300 x 300 DPI)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The RECORD statement – checklist of items, extended from the STROBE statement, that should be reported in observational studies using routinely collected health data.

	Item No.	STROBE items	Location in manuscript where items are reported	RECORD items	Location in manuscript where items are reported
Title and abstract					
	1	(a) Indicate the study's design with a commonly used term in the title or the abstract (b) Provide in the abstract an informative and balanced summary of what was done and what was found	Title and abstract	RECORD 1.1: The type of data used should be specified in the title or abstract. When possible, the name of the databases used should be included. RECORD 1.2: If applicable the geographic region and timeframe within which the study took place should be reported in the title or abstract. RECORD 1.3: If linkage between databases was conducted for the study, this should be clearly stated in the title or abstract.	Abstract p. 2 Abstract p. 2 Abstract p. 2
Introduction					
Background rationale	2	Explain the scientific background and rationale for the investigation being reported			Introduction p. 5-6
Objectives	3	State specific objectives, including any prespecified hypotheses			Introduction p. 6
Methods					
Study Design	4	Present key elements of study design early in the paper			Methods p. 7-9
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection			Methods p. 7-9
Participants	6	(a) <i>Cohort study</i> - Give the eligibility criteria, and the		RECORD 6.1: The methods of study population selection (such as codes or	Methods p. 7-9 Table 1

		<p>sources and methods of selection of participants. Describe methods of follow-up</p> <p><i>Case-control study</i> - Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls</p> <p><i>Cross-sectional study</i> - Give the eligibility criteria, and the sources and methods of selection of participants</p> <p>(b) <i>Cohort study</i> - For matched studies, give matching criteria and number of exposed and unexposed</p> <p><i>Case-control study</i> - For matched studies, give matching criteria and the number of controls per case</p>		<p>algorithms used to identify subjects) should be listed in detail. If this is not possible, an explanation should be provided.</p> <p>RECORD 6.2: Any validation studies of the codes or algorithms used to select the population should be referenced. If validation was conducted for this study and not published elsewhere, detailed methods and results should be provided.</p> <p>RECORD 6.3: If the study involved linkage of databases, consider use of a flow diagram or other graphical display to demonstrate the data linkage process, including the number of individuals with linked data at each stage.</p>	<p>NA, used standard clinical codes</p> <p>Figure 1</p>
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable.		RECORD 7.1: A complete list of codes and algorithms used to classify exposures, outcomes, confounders, and effect modifiers should be provided. If these cannot be reported, an explanation should be provided.	Methods p. 7-9 [calculated odds ratios]
Data sources/ measurement	8	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group			Methods p. 7-9 Read codes in GP data ICD-10 codes in PEDW data
Bias	9	Describe any efforts to address potential sources of bias			Methods p. 7-9 Case-control comparison only

36/bmjopen-2024-019031-365 Downloaded from http://bmjopen.bmj.com/ on April 19, 2024 by guest. Protected by copyright.

					for years and GP practices with good data coverage
Study size	10	Explain how the study size was arrived at			Methods p. 7-9 Combined first diagnoses in GP and PEDW
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why			Methods p. 7-9
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding (b) Describe any methods used to examine subgroups and interactions (c) Explain how missing data were addressed (d) <i>Cohort study</i> - If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> - If applicable, explain how matching of cases and controls was addressed <i>Cross-sectional study</i> - If applicable, describe analytical methods taking account of sampling strategy (e) Describe any sensitivity analyses			Methods p. 7-9 a) Simple odds ratios b) Simple counts c) NA (based on diagnoses) d) Cohort – NA Case-control: week of birth and gender, dependant on registration with GP e) NA
Data access and cleaning methods		..		RECORD 12.1: Authors should describe the extent to which the investigators had access to the database population used to create the study	Methods p 7-9

				population. RECORD 12.2: Authors should provide information on the data cleaning methods used in the study.	Methods p. 7-9
Linkage		..		RECORD 12.3: State whether the study included person-level, institutional-level, or other data linkage across two or more databases. The methods of linkage and methods of linkage quality evaluation should be provided.	Methods p. 7-9
Results					
Participants	13	(a) Report the numbers of individuals at each stage of the study (<i>e.g.</i> , numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed) (b) Give reasons for non-participation at each stage. (c) Consider use of a flow diagram		RECORD 13.1: Describe in detail the selection of the persons included in the study (<i>i.e.</i> , study population selection) including filtering based on data quality, data availability and linkage. The selection of included persons can be described in the text and/or by means of the study flow diagram.	Results p. 9-12 Figure 1
Descriptive data	14	(a) Give characteristics of study participants (<i>e.g.</i> , demographic, clinical, social) and information on exposures and potential confounders (b) Indicate the number of participants with missing data for each variable of interest (c) <i>Cohort study</i> - summarise follow-up time (<i>e.g.</i> , average and total amount)			a) p. 9-12 b) only exact matches, cannot identify missing data c) NA
Outcome data	15	<i>Cohort study</i> - Report numbers of outcome events or summary measures over time <i>Case-control study</i> - Report			p. 9-12 cohort: total number of people diagnosed in


36/bmjopen-2019-003365 on 19 April 2024 by guest. Protected by copyright.

		numbers in each exposure category, or summary measures of exposure <i>Cross-sectional study</i> - Report numbers of outcome events or summary measures			either GP or PEDW case-control: odds ratios
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% confidence interval). Make clear which confounders were adjusted for and why they were included (b) Report category boundaries when continuous variables were categorized (c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period			p. 9-12 a) Simple odds ratios b) Based on Read chapters c) NA
Other analyses	17	Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses			Young people vs. adults Results p. 11
Discussion					
Key results	18	Summarise key results with reference to study objectives			p. 12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias		RECORD 19.1: Discuss the implications of using data that were not created or collected to answer the specific research question(s). Include discussion of misclassification bias, unmeasured confounding, missing data, and changing eligibility over time, as they pertain to the study being reported.	p. 12-13
Interpretation	20	Give a cautious overall interpretation of results considering objectives,			p. 12-13

		limitations, multiplicity of analyses, results from similar studies, and other relevant evidence		
Generalisability	21	Discuss the generalisability (external validity) of the study results		Discussion p. 12
Other Information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based		p. 14
Accessibility of protocol, raw data, and programming code		..	RECORD 22.1: Authors should provide information on how to access any supplemental information such as the study protocol, raw data, or programming code.	p. 16 data sharing statement

*Reference: Benchimol EI, Smeeth L, Guttman A, Harron K, Moher D, Petersen I, Sørensen HT, von Elm E, Langhin SM, the RECORD Working Committee. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. *PLoS Medicine* 2015; in press.

*Checklist is protected under Creative Commons Attribution ([CC BY](https://creativecommons.org/licenses/by/4.0/)) license.



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47